paclitaxel has been researched along with Peritoneal Carcinomatosis in 485 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (5.15) | 18.2507 |
| 2000's | 167 (34.43) | 29.6817 |
| 2010's | 236 (48.66) | 24.3611 |
| 2020's | 57 (11.75) | 2.80 |
| Authors | Studies |
|---|---|
| Barraja, P; Carbone, A; Cirrincione, G; De Cesare, M; Diana, P; Doldi, V; Lopergolo, A; Montalbano, A; Parrino, B; Pennati, M; Sbarra, S; Spanò, V; Zaffaroni, N | 1 |
| Barraja, P; Carbone, A; Cilibrasi, V; Cirrincione, G; Cominetti, D; Diana, P; Lopergolo, A; Montalbano, A; Parrino, B; Pennati, M; Spanò, V; Zaffaroni, N; Zuco, V | 1 |
| Arai, H; Boku, N; Hara, H; Hyodo, I; Inoue, E; Muro, K; Nakajima, TE; Nakamura, S; Nishina, T; Sasako, M; Shinozaki, K; Shitara, K; Terashima, M; Tsuda, M; Yamaguchi, K | 1 |
| Bixel, K; Brady, MF; Burger, RA; Casey, AC; Cosgrove, C; duPont, NC; Enserro, D; Fujiwara, K; Monk, BJ; Moxley, K; Rubin, S; Soper, J; Tewari, KS; Thaker, P; Wahner Hendrickson, AE; Walker, JL | 1 |
| Feng, T; Li, C; Mei, Y; Shi, M; Yan, C; Yan, M; Yuan, H; Zhang, J; Zhu, Z | 1 |
| Hiraki, Y; Imano, M; Kato, H; Momose, K; Nishida, S; Shinkai, M; Shiraishi, O; Tsubaki, M; Yasuda, A; Yasuda, T | 1 |
| Chen, MM; Feng, RH; He, CY; Hua, ZC; Li, C; Liu, WT; Lu, S; Ni, ZT; Sah, BK; Wang, ZQ; Yan, C; Yan, M; Yang, ZY; Yao, XX; Zheng, YN; Zhu, ZG; Zhu, ZL | 1 |
| Casas-Murillo, CA; González-Díaz, SN; López-Méndez, A; Santos-Fernández, WJ; Solís-Lara, H; Vidal-Gutiérrez, O; Villarreal-González, RV; Zayas-Villanueva, OA | 1 |
| Fujii, T; Hashimoto, D; Hirano, S; Honda, G; Kitayama, J; Kodera, Y; Miura, F; Motoi, F; Satoi, S; Sekimoto, M; Shimokawa, T; Uemura, K; Ueno, H; Unno, M; Yamaki, S; Yamamoto, T; Yamaue, H; Yoshitomi, H | 1 |
| Badau, LM; Ciocoiu, AD; Gheju, A; Oprean, CM; Segarceanu, NA; Vlaicu, B | 1 |
| Sugarbaker, PH | 1 |
| Bressler, E; Colson, YL; Ekladious, I; Grinstaff, MW; Hung, YP; Liu, R; Martin, A; Neal, EJ; Sabatelle, RC | 1 |
| Fushimi, A; Higaki, K; Kono, Y; Ogawara, KI; Yoshizawa, Y | 1 |
| Aerts, JGJV; Brandt-Kerkhof, ARM; Burger, JWA; Dietz, MV; Guchelaar, NAD; Koolen, SLW; Madsen, EVE; Mathijssen, RHJ; van Kooten, JP; Verhoef, C | 1 |
| Ma, J; Zhang, S | 1 |
| Enomoto, T; Fukuhara, S; Kamijima, S; Mandai, M; Ogino, K; Sugitani, Y; Ueda, A; Watari, H | 1 |
| Baumann, K; Belau, A; Burges, A; Canzler, U; de Gregorio, N; Denschlag, D; El-Balat, A; Emons, G; Gropp-Meier, M; Hanker, LC; Harter, P; Hartkopf, AD; Hasenburg, A; Heubner, ML; Hilpert, F; Jackisch, C; Joly, F; Kristensen, G; Kurtz, JE; Lück, HJ; Mahner, S; Meier, W; Park-Simon, TW; Pautier, P; Pfisterer, J; Rau, J; Schmalfeldt, B; Schröder, W; Sehouli, J; Selle, F | 1 |
| Bohart, RD; Goldstein, BH; Micha, JP; Rettenmaier, MA | 1 |
| Hiraki, Y; Imano, M; Kato, H; Kimura, Y; Momose, K; Shinkai, M; Shiraishi, O; Teranishi, H; Yasuda, A; Yasuda, T | 1 |
| Dayyani, F; Senthil, M | 1 |
| Emoto, S; Gohda, Y; Ishigami, H; Ishihara, S; Kashiwabara, K; Kitayama, J; Matsuzaki, H; Murono, K; Nozawa, H; Sasaki, K; Yamaguchi, H; Yokoyama, Y | 1 |
| Alban, LBV; Charruf, AZ; Dias, AR; Gregorio, JVAM; Hoff, PMG; Mello, ES; Moniz, CMV; Pereira, MA; Ramos, MFKP; Ribeiro Junior, U; Victor, CR; Zilberstein, B | 1 |
| Au, JLS; Chan, CHF; Lu, Z; Turaga, K; Wientjes, MG | 1 |
| Buckarma, E; Grotz, TE; Jin, Z; Thiels, CA | 1 |
| Akagi, Y; Hashimoto, K; Hino, H; Horiuchi, H; Matono, S; Matsuo, T; Nagano, T; Shimomura, S; Sueyoshi, S; Uchida, S | 1 |
| Blontzos, N; Iavazzo, C; Kalinoglou, N; Vafias, E; Vorgias, G | 1 |
| Ishigami, H; Kanda, M; Kitayama, J; Kobayashi, D; Kodera, Y; Tanaka, C; Yamaguchi, H | 1 |
| Goedken, M; Hatefi, A; Javidian, P; Louro, P; Malekshah, OM; Nomani, A; Patel, N; Polunas, M; Sarkar, S | 1 |
| Jimi, T; Kaneda, M; Kitai, M; Matsuoka, K; Nagao, S; Shibutani, T; Shiozaki, T; Sudo, T; Suzuki, K; Yamaguchi, S; Yamamoto, K; Yano, H | 1 |
| Aghajanian, C; Armstrong, DK; Bell-McGuinn, KM; Chen, A; Duska, LR; Fracasso, PM; Gordon, S; Gray, HJ; Guntupalli, SR; Hagemann, AR; Mathews, CA; Miller, A; Moore, KN; O'Cearbhaill, RE; O'Malley, D; Schilder, RJ; Walker, JL | 1 |
| Awasthi, N; Hassan, MS; Li, J; Schwarz, MA; Schwarz, RE; von Holzen, U; Williams, F | 1 |
| Iida, Y; Odajima, S; Okamoto, A; Saito, M; Tabata, J; Ueda, K; Yamada, K; Yanaihara, N; Yokomizo, R | 1 |
| Chang, HK; Chang, SJ; Han, SS; Kim, DY; Kim, HS; Kim, J; Kim, S; Lee, JW; Lee, KH; Park, SJ; Park, SY; Shim, SH | 1 |
| Ajani, J; Badgwell, B; Blum Murphy, M; Das, P; Estrella, J; Ikoma, N; Mansfield, P; Minsky, BD; Roy-Chowdhuri, S; Song, S; Wang, X | 1 |
| Aieta, M; Chiriacò, G; Conca, R; Corona, SP; D'Angelo, A; Multari, AG; Paganini, G; Petrioli, R; Rosellini, P; Roviello, G | 1 |
| Boku, N; Hara, H; Hyodo, I; Katayama, H; Mizusawa, J; Muro, K; Nakajima, TE; Nakamura, S; Nishina, T; Sakamoto, T; Shinozaki, K; Shitara, K; Terashima, M; Yamaguchi, K | 1 |
| Burger, R; Coleman, RL; Handley, KF; Molin, GZD; Moore, KN; Sood, AK; Stagg, R | 1 |
| Kubo, S; Tomita, N; Yamano, T | 1 |
| Chang, SJ; Ji, YI; Kim, HS; Kim, JW; Kim, SY; Kwon, SH; Lee, EJ; Lee, M; Lee, SH; Lee, SJ; Park, S; Park, SJ; Roh, JW; Shim, SH; Song, T | 1 |
| Emoto, S; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nozawa, H; Otani, K; Sasaki, K; Sonoda, H | 1 |
| Stuart, OA; Sugarbaker, PH | 1 |
| Eguchi, H; Goda, K; Hashimoto, Y; Ikeda, M; Imaoka, H; Kan, M; Kimura, G; Mitsunaga, S; Ohno, I; Otsuru, T; Sasaki, M; Suzuki, Y; Takahashi, H; Umemoto, K; Watanabe, K | 1 |
| Fujii, T; Hayashi, M; Hirano, S; Inoue, H; Ishikawa, H; Kitayama, J; Kodera, Y; Motoi, F; Murakami, Y; Murotani, K; Satoi, S; Sekimoto, M; Shibuya, K; Sonohara, F; Takami, H; Yamada, S; Yamaki, S; Yamamoto, T; Yoshioka, I | 1 |
| Bonney, GK; Charles, CJ; Cheow, ES; Chue, KM; Goh, BC; Jang, CJ; Kim, G; Li, RR; Looi, WD; Shabbir, A; So, JB; Sundar, R; Tai, CH; Tan, HL; Wang, L; Yong, WP | 1 |
| Aghajanian, C; Banerjee, S; Berger, R; Boyd, AP; Christy-Bittel, J; Churruca, C; Cibula, D; Clamp, A; Coleman, RL; Colombo, N; Del Campo, JM; Drill, E; Grisham, RN; Hilpert, F; Kalbacher, E; Kristensen, G; Marth, C; Mirza, MR; Monk, BJ; Moore, KN; O'Malley, DM; Oehler, MK; Oza, AM; Pignata, S; Ray-Coquard, I; Romero, I; Sehouli, J; Vergote, I; Vuylsteke, P; Westermann, A | 1 |
| Hayata, K; Katsuda, M; Kitadani, J; Nakamori, M; Nakamura, M; Ojima, T; Yamaue, H | 1 |
| Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY | 1 |
| Arai, H; Kawahira, M; Masuishi, T; Muro, K; Nakajima, TE; Yasui, H | 1 |
| Arjona-Sanchez, A; Aziz, O; Briceño, J; Casado-Adam, A; Esquivel, J; Glehen, O; Nedelcut, DS; Passot, G; Piso, P; Rodriguez-Ortiz, L; Rufian-Peña, S; Salti, G; Sanchez-Hidalgo, JM; Selvasekar, CR; Sommariva, A; Turaga, K; Van der Speeten, K; Yonemura, Y | 1 |
| Ishigami, H; Kitayama, J; Lefor, AK; Saito, S; Sata, N; Yamaguchi, H | 1 |
| Hashimoto, Y; Hirahara, S; Kobayashi, H; Kubota, H; Kuhara, Y; Miyamoto, K; Sakashita, Y; Shirakawa, K; Toyota, K; Yano, R; Yokoyama, Y | 1 |
| Akagi, S; Ando, H; Fujita, K; Ishida, T; Ishima, Y; Kusano, T; Matsushima, T; Shimizu, T; Tajima, K | 1 |
| Irrinki, S; Kurdia, K; Yadav, T | 1 |
| Fujii, T; Satoi, S; Yamada, S | 2 |
| Chang, CS; Chiu, CC; Hsieh, MC; Pei, SN; Rau, KM; Tsai, YF | 1 |
| Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Fuyama, S; Higashi, T; Mase, K; Mizutani, M; Moriya, T; Ozawa, K; Takagi, S; Takei, S; Takeshita, A; Yokoyama, M | 1 |
| Backes, FJ; Bixel, K; Chen, M; Cohn, DE; Copeland, LJ; Cosgrove, C; Dzwigalski, K; Fowler, JM; Hays, J; Hill, K; O'Malley, D; Phelps, M; Poi, M; Salani, R; Wei, L | 1 |
| Ikeda, T; Kaneda, M; Kondo, E; Maki, S; Nii, M; Nimura, R; Tabata, T; Yoshida, K | 1 |
| Azevedo, RB; Bonadio, RS; de Lima, LI; de Matos Neto, JN; de Oliveira, MC; Faria, RS; Longo, JPF; Moya, SE; Roque, MC | 1 |
| Avallone, A; Capozzi, M; Cavalcanti, E; DE Divitiis, C; DI Girolamo, E; Nasti, G; Ottaiano, A; Romano, G; Tafuto, S; Tatangelo, F; VON Arx, C | 1 |
| Enami, C; Hyodo, I; Iwai, K; Matano, D; Moriwaki, T; Nagase, M; Niisato, Y; Suganuma, D; Takagi Taketa, K; Tange, Y; Yamamoto, Y; Yamaura, M | 1 |
| Armstrong, DK; Ashfaq, R; Basen-Engquist, K; Brady, MF; Chan, JK; Coleman, RL; Davidson, SA; DiSilvestro, P; Fujiwara, K; Herzog, TJ; Huang, H; Kim, BG; Mannel, RS; O'Malley, DM; Rubin, SC; Sabbatini, P; Spirtos, NM; Tewari, KS; Walker, JL | 1 |
| Ishigami, H; Kitayama, J; Kurihara, M; Satoh, Y; Yamaguchi, H; Yatomi, Y | 1 |
| Celebi, K; Kaban, A; Saip, P; Salihoglu, Y; Sozen, H; Topuz, S | 1 |
| Aoki, D; Hashimoto, S; Hirano, T; Hirasawa, A; Iwasa, N; Kataoka, F; Makabe, T; Nanki, Y; Nomura, H; Sakai, K; Yamagami, W; Yoshihama, T | 1 |
| Bun, S; Ebata, T; Fujiwara, Y; Kato, T; Kodaira, M; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yoshida, H; Yunokawa, M | 1 |
| Espinosa Lara, P; Jiménez-Reyes, J; Medina-Puente, C; Riquelme Oliveira, A | 1 |
| Barrios, P; Cascales-Campos, P; Esteve-Pérez, N; Morales-Soriano, R; Segura-Sampedro, JJ | 1 |
| Misumi, T; Seo, S; Suzuki, T; Tashiro, H | 1 |
| Hata, T; Hayashi, H; Iseki, M; Kanno, A; Kyakumoto, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Sakata, N; Shimosegawa, T; Takadate, T; Unno, M | 1 |
| Bae, WK; Cherukula, K; Lee, JH; Park, IK | 1 |
| Gao, J; Liu, Q; Qiu, N; Shen, Y; Wang, J | 1 |
| Alessandro Peccatori, F; Bani, MR; Bizzaro, F; Colombo, N; D'Agostini, E; Decio, A; Erba, E; Falcetta, F; Giavazzi, R; Minoli, L; Scanziani, E; Ubezio, P; Zucchetti, M | 1 |
| Becker, DA; Bevis, KS; Leath, CA; Smith, BQ; Walters-Haygood, CL | 1 |
| Amagai, K; Boku, N; Chin, K; Choda, Y; Esaki, T; Fujii, H; Fujitani, K; Fukushima, N; Goto, M; Hara, H; Hara, T; Hironaka, S; Kimura, Y; Koeda, K; Koizumi, W; Machida, N; Morita, S; Muro, K; Nakayama, N; Nishikawa, K; Ohta, M; Sato, A; Shimura, M; Shitara, K; Takano, T; Takashima, A | 1 |
| An, C; Bang, S; Cho, IR; Chung, JB; Chung, MJ; Jo, JH; Jung, SY; Kang, H; Lee, HS; Park, JY; Park, MS; Park, SW; Song, SY | 1 |
| Kruitwagen, RF; Lalisang, RI; Sonke, GS; Timmermans, M; Van de Vijver, KK; van der Aa, MA; Witteveen, PO | 1 |
| Bodurka, DC; Bookman, MA; Friedlander, M; Geller, M; Glaser, G; Herzog, TJ; Java, JJ; Krivak, TC; Lee, RB; Mutch, DG; O'Malley, DM; Olawaiye, AB; Wenham, RM | 1 |
| Chiba, Y; Hiraki, Y; Imano, M; Iwama, M; Kato, H; Kimura, Y; Nishida, S; Shinkai, M; Shiraisi, O; Tsubaki, M; Yasuda, A; Yasuda, T | 1 |
| Chiba, Y; Hiraki, Y; Imano, M; Iwama, M; Kato, H; Kimura, Y; Nishida, S; Shinkai, M; Shiraishi, O; Tsubaki, M; Yasuda, A; Yasuda, T | 1 |
| Aghajanian, C; Bonebrake, AJ; Dewdney, SB; Johnston, CM; Kauderer, JT; Monk, BJ; Moxley, KM; Secord, AA; Ueland, FR | 1 |
| Emoto, S; Hata, K; Hiyoshi, M; Ishihara, S; Ishimaru, K; Kaneko, M; Kawai, K; Muro, K; Murono, K; Nagata, H; Nishikawa, T; Nozawa, H; Otani, K; Sasaki, K; Shuno, Y; Tanaka, T | 1 |
| Ishigami, H | 1 |
| Ji, J; Li, Z; Xue, K; Ying, X | 1 |
| Antonuzzo, L; Aprile, G; Avallone, A; Bordonaro, R; Cinieri, S; Di Donato, S; Fanotto, V; Fornaro, L; Gerratana, L; Giampieri, R; Leone, F; Melisi, D; Nichetti, F; Pellegrino, A; Rimassa, L; Rosati, G; Santini, D; Scartozzi, M; Silvestris, N; Stragliotto, S; Tomasello, G; Vasile, E | 1 |
| Aghajanian, C; Bender, DP; Carlson, JW; Crane, EK; Darus, CJ; Makker, V; Mannel, RS; Matulonis, UA; Mutch, DG; Sill, MW | 1 |
| Aieta, M; Chiriacò, G; Conca, R; Multari, AG; Paganini, G; Petrioli, R; Rosellini, P; Roviello, G | 1 |
| Akaishi, T; Hakamada, K; Hara, Y; Kubo, N; Mitsuhashi, Y; Muroya, T; Ogasawara, H; Sato, K; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yoshida, E; Yoshida, T | 1 |
| Bakrin, N; Gladieff, L | 1 |
| Kubo, T; Kuwata, T; Mihara, K; Ochiai, A; Seyama, T; Yanagihara, K; Yokozaki, H | 1 |
| Alberca, A; Baladron, V; Estella, A; Faba, P; Fernandez, E; Fernández, J; Marta, P; Martín, J; Montenegro, O; Oyarzabal, J; Padilla-Valverde, D; Palomino, T; Redondo, J; Sanchez, S; Villarejo, P | 1 |
| Amano, S; Goto, A; Hanai, T; Hattori, Y; Inaba, K; Kadoya, S; Kato, Y; Kikuchi, K; Nakamura, K; Nakauchi, M; Sugioka, A; Tomatsu, M; Tsuru, Y; Uyama, I | 1 |
| Calzas, J; Carrión, L; Manzanedo, I; Martínez-Torres, B; Pereira, F; Pérez-Viejo, E; Serrano, Á | 1 |
| Chang, CW; Chen, CH; Cheng, CJ; Chiu, YH; Fu, HS; Liu, WM; Wang, ID; Wu, YC | 1 |
| Akladios, C; Alfonsi, P; Bakrin, N; Ballester, M; Bendifallah, S; Bolze, PA; Bonnet, F; Bourgin, C; Chabbert-Buffet, N; Collinet, P; Courbiere, B; Daraï, E; De la Motte Rouge, T; Devouassoux-Shisheboran, M; Falandry, C; Ferron, G; Fournier, L; Gladieff, L; Golfier, F; Gouy, S; Guyon, F; Huchon, C; Lambaudie, E; Lavoue, V; Leary, A; Leblanc, E; Lecuru, F; Lefrere-Belda, MA; Lemoine, A; Narducci, F; Ouldamer, L; Pautier, P; Planchamp, F; Pouget, N; Ray-Coquard, I; Rousset-Jablonski, C; Senechal-Davin, C; Thomassin-Naggara, I; Touboul, C; Uzan, C; You, B | 1 |
| Bamias, A; Colombo, N; Covens, A; Del Campo, JM; Kroep, JR; Ma, H; Marth, C; Meier, W; Monk, BJ; O'Malley, DM; Park, SY; Pickett, CA; Raza Mirza, M; Scambia, G; Van Calster, B; Vergote, I; Wenham, RM | 1 |
| Amiji, MM; Menon, D; Nair, SV; Padmakumar, S; Parayath, NN | 1 |
| Hirose, Y; Ishii, A; Ishimoto, U; Iwaku, A; Kinoshita, A; Koike, K; Mizuno, Y; Saruta, M; Shibata, K; Shoji, R; Yokota, T | 1 |
| Baratti, D; Deraco, M; Guaglio, M; Kusamura, S; Nizri, E; Rajendra, VJ; Salcedo-Hernández, RA; Sinukumar, S | 1 |
| Aoki, M; Boku, N; Hirano, H; Honma, Y; Imazeki, H; Ishikawa, M; Iwasa, S; Kato, K; Nagashima, K; Okita, N; Saruta, M; Shoji, H; Takashima, A | 1 |
| Blaakaer, J; Christiansen, T; Iversen, LH; Mikkelsen, MS; Petersen, LK | 1 |
| Kaye, SB; Kipps, E; Tan, DS | 1 |
| Mutasim, DF; Spicknall, KE | 1 |
| Armstrong, DK; Coleman, RL; Phillips, M; Weil, SC; White, AJ | 1 |
| Apte, SM; Bou Zgheib, N; Gonzalez-Bosquet, J; Judson, PL; Lancaster, JM; Roberts, WS; Teefey, P; Wenham, RM | 1 |
| Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Mendivil, AA; Micha, JP; Rettenmaier, MA | 2 |
| Imano, M; Okuno, K | 1 |
| Dhillon, S | 1 |
| Goto, S; Kamigaki, T; Saito, M; Yano, K | 1 |
| Emoto, S; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H | 1 |
| Katayama, K; Nishino, T; Okitsu, H; Okitsu, N; Takahashi, Y; Tanaka, T | 1 |
| Bookman, MA; Brady, MF; Burger, RA; Kong, G; Nguyen, HP; Rhee, J; Sovak, MA | 1 |
| Aoki, D; Isonishi, S; Jobo, T; Katsumata, N; Kimura, E; Kodama, S; Michimae, H; Ochiai, K; Sugiyama, T; Takahashi, F; Terauchi, F; Yasuda, M | 1 |
| Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H | 1 |
| Fujiwara, K; Iwasaki, S; Muraji, M; Nishimura, R; Sudo, T; Ueno, S; Wakahashi, S; Yamaguchi, S | 1 |
| Enomoto, N; Hamaguchi, T; Honma, Y; Iwasa, S; Kadokura, M; Kato, K; Shimada, Y; Yamada, Y | 1 |
| Chen, W; Li, H; Tong, L; Wu, J | 1 |
| Cho, H; Fujikawa, H; Iwasaki, K; Kasahara, A; Masuda, M; Ogata, T; Osaragi, T; Rino, Y; Shirai, J; Sujishi, K; Tsuburaya, A; Yamada, T; Yamamoto, Y; Yoneyama, K; Yoshikawa, T | 1 |
| Ebisui, C; Fukuchi, N; Kato, R; Kinuta, M; Makino, S; Murata, K; Okada, K; Okamura, S; Takeoka, T; Wada, Y; Yanagisawa, T; Yokouchi, H | 1 |
| Akita, H; Fujiwara, Y; Gotoh, K; Ishigami, H; Kishi, K; Kitayama, J; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohue, M; Sakon, M; Sasaki, K; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Araki, T; Ide, S; Inoue, Y; Kitajima, T; Kondo, S; Kusunoki, M; Mizoguchi, A; Mohri, Y; Ohi, M; Okigami, M; Saigusa, S; Shimura, T; Tanaka, K; Toiyama, Y; Uchida, K | 1 |
| Goto, Y; Kato, H; Matano, Y; Nishino, A; Tsukayama, S; Yoshimitsu, M | 1 |
| Awtrey, CS; Battelli, C; Buss, MK; Campo, M; Konstantinopoulos, PA | 1 |
| Au, JL; Cole, DJ; Lu, Z; Wang, J; Wientjes, MG; Yeung, BZ | 1 |
| Emoto, S; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H | 2 |
| González Ruiz de la Herrán, F; Haya Palazuelo, J; López de la Manzanara Cano, C; Martín Fernández, J; Padilla Valverde, D; Pascual-Ramírez, J; Sánchez García, S; Villarejo Campos, P | 1 |
| García-Rojo, M; Martín-Fernández, J; Padilla-Valverde, D; Rodríguez-Martínez, M; Sánchez-García, S; Villarejo-Campos, P | 1 |
| Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ | 1 |
| Bookman, MA; Gatcliffe, TA; Java, JJ; Monk, BJ; Tewari, KS | 1 |
| Baranowski, W; Bodnar, L; Cichowicz, M; Cierniak, S; Dąbek, A; Gąsowska-Bodnar, A; Jerzak, M; Kozłowski, W | 1 |
| Aisu, N; Hoshino, S; Maki, K; Naito, M; Nakagawa, M; Yamashita, Y; Yoshida, Y | 1 |
| Boussery, K; Ceelen, W; Colin, P; De Smet, L; Remon, JP; Van Bocxlaer, J; Vermeulen, A; Vervaet, C | 1 |
| Fujimura, T; Furukawa, H; Fushida, S; Hayashi, H; Hirakawa, K; Inokuchi, M; Kinoshita, J; Makino, I; Masakazu, Y; Miyashita, T; Nakagawara, H; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Shoji, M; Tajima, H; Takamura, H; Tsukada, T; Watanabe, T | 1 |
| Aktas, B; Alici, S; Aslan, K; Buyukberber, S; Cinkir, HY; Demirci, U; Günaydın, Y; Inal, A; Oksuzoglu, B; Ozatli, T; Oztop, I; Unal, OU; Uncu, D; Yazici, O; Yilmaz, AU | 1 |
| Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
| Hirano, M; Ichinose, M; Mizumoto, A; Ozamoto, Y; Takao, N; Tatsuno, M; Togawa, T; Yamamoto, Y; Yonemura, Y | 1 |
| Cascales-Campos, PA; Feliciangeli, E; Gil, E; Gil, J; González-Gil, A; López, V; Nieto, A; Parrilla, JJ; Parrilla, P; Ruiz-Pardo, J | 1 |
| Arjona-Sánchez, A; Briceño Delgado, J; Casado-Adam, A; Garcilazo Arismendi, DJ; Gómez-Luque, I; Medina Fernández, FJ; Muñoz-Casares, FC; Rufián Peña, S; Thoelecke, H | 1 |
| Baidoo, KE; Brechbiel, MW; Milenic, DE; Yong, KJ | 1 |
| Cho, H; Kim, JH; Kim, S; Kim, SW; Kim, YT; Lee, M; Nam, EJ | 1 |
| Becker, HG | 1 |
| Chevreau, C; Culine, S; Delva, R; Eymard, JC; Fizazi, K; Fléchon, A; Geoffrois, L; Gravis, G; Habibian, M; Journeau, F; Kerbrat, P; Laplanche, A; Linassier, C; Logothetis, C; Malhaire, JP; Mardiak, J; Martin, AL; Pagliaro, L; Reckova, M; Rolland, F; Roubaud, G; Theodore, C | 1 |
| Ansaloni, L; Ballerini, A; Bertoli, P; Busci, LM; Cambria, F; Ceresoli, M; Coccolini, F; D'Incalci, M; Frigerio, L; Grosso, G; Lotti, M; Morosi, L; Pisano, M; Rossetti, D; Zucchetti, M | 1 |
| Sánchez-García, S | 1 |
| Castelo, B; Espinosa, E; Pinto, A; Redondo, A; Zamora, P | 1 |
| Akita, H; Hayasaka, J; Kondo, M; Kusano-Kitazume, A; Ohtaka, Y; Okamoto, E; Shibayama, T; Suenobu, Y; Takagi, K; Tamura, A; Tei, S; Watanabe, A | 1 |
| Fujii, K; Iwai, N; Kataoka, K; Masuzawa, A; Matsumoto, N; Morita, Y; Takada, R; Takami, S; Takaya, H; Tanaka, N; Wakabayashi, N; Yoriki, H | 1 |
| Katsumata, N | 1 |
| Fukuda, T; Hashiguchi, Y; Ichimura, T; Imai, K; Sumi, T; Teramae, M; Yamauchi, M; Yasui, T | 1 |
| Baltezor, MJ; Decedue, CJ; diZerega, GS; Espinosa, J; Johnson, GA; Mackay, CB; Markman, M; Maulhardt, HA; McMeekin, DS; Moore, KM; Reed, GA; Roby, KF; Schulz, TK; Smith, HJ; Weir, SJ; Wick, JA; Williamson, SK | 1 |
| Emoto, S; Hanafusa, N; Ishigami, H; Ito, T; Kitayama, J; Watanabe, T; Yamaguchi, H | 1 |
| Aramendía, JM; D'Amelio, CM; Fusco, JP; Gastaminza, G; Goikoetxea, MJ; Yuste, JR | 1 |
| Au, JL; Lu, Z; Wientjes, MG | 1 |
| Cozma, A; Muntean, V; Simescu, R; Şimon, I; Togănel, RD; Zolog, A | 1 |
| Dartigues, P | 1 |
| Au, JL; Cole, DJ; Cui, M; Lu, Z; Wang, J; Wientjes, MG; Yeung, BZ | 1 |
| Alexander, H; Banerjee, S; Barton, D; Bodla, S; Georgiou, A; Gore, M; Kaye, S; McLachlan, J; Nobbenhuis, M; Seifert, H | 1 |
| Burger, RA; Cohn, DE; Duska, LR; Java, JJ | 1 |
| Fushida, S; Hayashi, H; Hirakawa, K; Kinoshita, J; Miyashita, T; Ninomiya, I; Ohbatake, Y; Ohta, T; Oyama, K; Tajima, H; Takamura, H; Tsukada, T; Yashiro, M | 1 |
| Amagai, K; Boku, N; Gotoh, M; Hamamoto, Y; Kawai, H; Mizusawa, J; Nakamura, K; Nakayama, N; Nishina, T; Ohtsu, A; Shimada, Y; Shirao, K; Yamaguchi, K; Yasui, H | 1 |
| Zhu, Z | 1 |
| Alexandrov, VA; Belyaev, AM; Belyaeva, OA; Bespalov, VG; Kireeva, GS; Kopteva, OS; Krasilnikova, LA; Maidin, MA; Semenov, AL; Stukov, AN; Vasilieva, IN; Vyshinskaya, EA | 1 |
| Bidziński, M; Bjørge, L; Colombo, N; de Gregorio, N; Del Campo, JM; Denison, U; du Bois, A; Harter, P; Heubner, M; Hilpert, F; Kristensen, G; Lortholary, A; Malander, S; Meier, W; Merger, M; Minarik, T; Mirza, MR; Nicoletto, MO; Ottevanger, P; Pfisterer, J; Pignata, S; Ray-Coquard, I; Reuss, A; Sailer, MO; Scambia, G; Sevin, E; Vergote, I | 1 |
| Arjona-Sánchez, Á; Briceño, FJ; Casado-Adam, Á; Medina-Fernández, FJ; Muñoz-Casares, FC; Muñoz-Villanueva, MC; Ortega-Salas, R; Rubio, MJ; Rufián-Peña, S; Sánchez-Hidalgo, JM | 1 |
| Cao, Y; Gao, J; Gong, J; Li, Y; Lu, Z; Shen, L; Zhang, Q | 1 |
| Emoto, S; Hata, K; Ishigami, H; Ishihara, S; Kawai, K; Kazama, S; Kitayama, J; Kiyomatsu, T; Nishikawa, T; Nozawa, H; Sunami, E; Tanaka, J; Tanaka, T; Watanabe, T; Yamaguchi, H | 1 |
| Fukunari, H; Hayashi, T; Kato, T; Nakao, K; Okajima, C; Shitara, K; Watanabe, G; Yamamoto, Y | 1 |
| Arimitsu, H; Chibana, T; Ikeda, A; Imanishi, S; Ishige, F; Kainuma, O; Kobayashi, R; Nabeya, Y; Sasaki, K; Souda, H; Takiguchi, N; Tonooka, T; Yamamoto, H | 1 |
| Akita, H; Fujiwara, Y; Gotoh, K; Kobayashi, S; Miyata, H; Miyoshi, N; Noura, S; Ohue, M; Omori, T; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Amano, H; Fukuda, T; Kawashima, M; Nakahara, M; Noriyuki, T; Ono, N; Saito, R; Sasada, T; Takei, D; Takemoto, Y; Yamaki, M; Yoshida, M | 1 |
| Chia, CS; Ong, WS; Soo, KC; Tan, GH; Teo, MC; Tham, CK | 1 |
| Battaglia, G; Braun, GB; Gaitzsch, J; Hunt, H; Ruoslahti, E; Scodeller, PD; Simón-Gracia, L; Teesalu, T; Willmore, AM | 1 |
| Ji, ZH; Li, Y; Peng, KW; Sun, JH; Wu, HT; Yonemura, Y; Zhang, Q | 1 |
| Amo-Salas, M; Martín-Fernández, J; Padilla-Valverde, D; Sánchez-García, S; Villarejo-Campos, P | 1 |
| Kakiuchi, Y; Takashima, H; Urano, S | 1 |
| Chaithongwongwatthana, S; Yanaranop, M | 1 |
| Awasthi, N; Grojean, M; Monahan, S; Schwarz, MA; Schwarz, RE; Scire, E; Zhang, E | 1 |
| Chang, WP; Chang, Y; Chang, YH; Chuang, CM; Lee, WH; Lu, CH; Yen, MS | 1 |
| Akkar, OB; Karadayi, K; Karakus, S; Kurt, A; Ugurlu, GP; Yanik, A; Yildiz, C | 1 |
| Deng, L; Dong, A; Fan, H; Tang, H; Xu, S; Yin, L; Zhang, J | 1 |
| Chi, DS; Gardner, GJ; Long Roche, K; Mueller, JJ; O'Cearbhaill, RE; Schlappe, BA; Sonoda, Y; Zivanovic, O | 1 |
| Achilefu, S; Betts, D; Bui, K; Cho, H; Kwon, GS; Liang, K; McKenzie, M; Suh, A; Tang, R | 1 |
| Kamura, T; Kasamatsu, T; Kawana, K; Kobayashi, H; Konishi, I; Nakamura, K; Nakanishi, T; Onda, T; Saito, M; Saito, T; Satoh, T; Takano, M; Takehara, K; Takeshima, N; Ushijima, K; Wakabayashi, M; Watanabe, Y; Yaegashi, N; Yokota, H; Yoshikawa, H | 1 |
| Colby, AH; Colson, YL; Gilmore, D; Grinstaff, MW; Liu, R; Padera, RF; Schulz, M; Shirihai, O; Zeng, J | 1 |
| Bun, S; Ebata, T; Fujiwara, Y; Hayashi, Y; Kato, T; Kodaira, M; Makino, Y; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M | 1 |
| Arévalo-Pérez, J; Barceló, F; Cascales-Campos, P; Gil, E; Gil, J; López-López, V; Nieto, A; Parrilla, P | 1 |
| Deme, D; Telekes, A | 1 |
| Bamias, A; Chmielowska, E; Colombo, N; Davidenko, I; DeCensi, A; Gadducci, A; González-Martín, A; Hegg, R; Joly, F; Korach, J; Martin, N; Mendiola, C; Oza, AM; Pautier, P; Robb, S; Selle, F; Zamagni, C; Zvirbule, Z | 1 |
| Bun, S; Ebata, T; Fujiwara, Y; Kato, T; Kodaira, M; Shimizu, C; Shimoi, T; Shimomura, A; Tamura, K; Yonemori, K; Yunokawa, M | 1 |
| Chereau, E; Colombo, PE; Cottu, P; Dupin, J; Fauvet, R; Floquet, A; Follana, P; Fourchotte, V; Ghazi, Y; Gouy, S; Joly, F; Kalbacher, E; Lambaudie, E; Lecuru, F; Lesoin, A; Martin-Francoise, S; Pomel, C; Rouzier, R; Selle, F; Zohar, S | 1 |
| Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP | 1 |
| Asakage, M; Ishigami, H; Kitayama, J; Yamaguchi, H; Yamashita, H | 1 |
| Fujii, T; Honda, G; Isayama, H; Ishigami, H; Kodera, Y; Kon, M; Kurata, M; Mizuma, M; Motoi, F; Satoi, S; Takahara, N; Unno, M; Yamada, S; Yamamoto, T; Yanagimoto, H | 1 |
| Fujimura, Y; Iwata, M; Kato, K; Maeda, K; Moriyama, T; Ohsawa, I; Sakamoto, T; Sanda, T; Tabata, M | 1 |
| Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC | 1 |
| Chang, D; Sugarbaker, PH | 1 |
| Awasthi, N; Hassan, MS; Li, J; Schwarz, MA; Schwarz, RE; von Holzen, U | 1 |
| Acocella, F; Ansaloni, L; Brizzola, S; Ceresoli, M; Coccolini, F; D'Incalci, M; Davoli, E; Ghiringhelli, M; Morosi, L; Zucchetti, M | 1 |
| Baekelandt, MM; Dugan, MH; Fracasso, PM; Gordon, AN; Joly, F; Jones, GJ; Lhommé, C; Lissoni, AA; Manikhas, GM; Mietlowski, WL; Nicoletto, MO; Walker, JL | 1 |
| Aghajanian, CA; DeRosa, FA; Gerst, SR; Hensley, ML; Konner, J; Sabbatini, PJ; Schilder, RJ; Spriggs, DR; Tew, WP | 1 |
| Aikins, JK; Allievi, C; Bookman, MA; Darcy, KM; DeGeest, K; Egorin, MJ; Mannel, RS; Morgan, MA; Rose, PG; Sill, MW | 1 |
| Saitou, T; Sasaki, H; Tokunaga, Y | 1 |
| Kaminishi, M; Shimoyama, S | 1 |
| Albert, PS; Baidoo, KE; Brady, ED; Brechbiel, MW; Flynn, J; Garmestani, K; Milenic, DE; Wong, KJ | 1 |
| Abu-Rustum, NR; Bains, M; Huang, M; Levine, DA; Rizk, N | 1 |
| Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Takahashi, K; Tsuno, NH; Yamada, J; Yamashita, H | 1 |
| Ikeguchi, M; Inoue, M; Matsumoto, S; Saito, H; Tsujitani, S | 1 |
| Adler, L; O'Malley, D; Sabbatini, P; Secord, AA; Sill, MW | 1 |
| Boterberg, T; Bouquet, W; Bracke, M; Ceelen, W; Pattyn, P; Peeters, M; Remon, JP; Vervaet, C | 1 |
| Atkinson, T; Horowitz, NS; Krag, KJ; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT | 1 |
| Gao, M; Gao, YN; Jiang, GQ; Wang, W; Yan, X; Zheng, H | 1 |
| Miki, H; Miyake, T; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Yoshimura, M | 1 |
| Alberts, DS; Liu, PY; Markman, M; Robinson, WR; Smith, HO; Tiersten, AD; Wilczynski, SP | 1 |
| Fukuda, H; Hatae, M; Iwasaka, T; Kamura, T; Kobayashi, H; Konishi, I; Nakanishi, T; Onda, T; Shibata, T; Yoshikawa, H | 1 |
| Alvarez, RD; Berry, E; Buttin, BM; Lurain, JR; Matthews, KS; Schink, J; Singh, DK | 1 |
| Chauffert, B; Combe, M; Delroeux, D; Demarchi, M; Guardiola, E; Heyd, B; Lorgis, V; Pivot, X; Royer, B; Stein, U | 1 |
| Accario-Winslow, C; Alberts, DS; Argenta, PA; Bookman, MA; Brady, MF; Burger, RA; Colombo, N; De Geest, K; Fowler, JM; Friedlander, M; Harper, PG; McGuire, WP; Mutch, DG; Roth, LM; Swart, AM; Trimble, EL | 1 |
| Asmar, L; Boehm, KA; Crozier, M; Encarnacion, C; Hancock, K; Messing, MJ; Teneriello, MG; Tseng, PC; Williams, A | 1 |
| Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H | 1 |
| Banz, C; Diedrich, K; Hornung, D; Noack, F; von Otte, S | 1 |
| Ando, T; Furuta, R; Goto, H; Ina, K; Kataoka, T; Kayukawa, S; Masaki, A; Nagao, S; Nishio, T | 1 |
| Argenta, PA; Geller, M; Ivy, JJ; Jonson, AL; Pierson, SM | 1 |
| Akamatsu, N; Aotani, E; Fujiwara, K; Kigawa, J; Miyagi, Y; Nagao, S; Noma, J; Numa, F; Okada, M | 1 |
| Ishigami, H; Ishihara, K; Kaisaki, S; Kamei, T; Kitayama, J; Konno, T; Nagawa, H; Soma, D; Yamada, J | 1 |
| Hidemura, A; Ishigami, H; Kaisaki, S; Kamei, T; Kato, M; Kitayama, J; Miyato, H; Nagawa, H; Otani, K; Soma, D; Yamashita, H | 2 |
| Ito, C; Kamijo, Y; Miyamoto, K; Nomura, M; Sai, Y | 1 |
| Fushida, S; Kimura, H; Mukawa, A | 1 |
| Alboni, C; Bernardi, A; Cacciari, N; Capizzi, E; D'Errico Grigioni, A; De Iaco, P; Denkert, C; Dietel, M; Martoni, AA; Massari, F; Quercia, S; Rosati, F; Rosati, M; Sehouli, J; Veltrup, E; Wirtz, RM; Zamagni, C | 1 |
| Hoekstra, AV; Hurteau, JA; Kirschner, CV; Rodriguez, GC | 1 |
| Ikeda, H; Kanagawa, T; Katoh, H; Kobayashi, K; Kodera, M; Oishi, M; Seshimo, K; Takita, K; Yamamura, M; Yamashita, Y; Yokomichi, N | 1 |
| Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Sood, AK | 1 |
| Bender, GP; Masellis, AM; Sielaff, TD | 1 |
| Amant, F; Bauknecht, T; Darstein, C; Kania, M; Michel, AL; Musib, L; Oskay-Oezcelik, G; Sehouli, J; Vergote, I | 1 |
| Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C | 1 |
| Fujimura, T; Fujita, H; Fushida, S; Harada, S; Hirakawa, K; Kayahara, M; Kinoshita, J; Kinuya, S; Ninomiya, I; Ohta, T; Oyama, K; Tsukada, T; Yagi, Y; Yashiro, M | 1 |
| Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M; Yoshioka, Y | 1 |
| Asami, S; Hirata, M; Idani, H; Kin, H; Kubo, S; Kumano, K; Kurose, Y; Muro, M; Nojima, H; Sasaki, H; Takakura, N; Yamashita, T; Yoshioka, T | 1 |
| Fujitani, K; Furukawa, H; Kimura, Y; Machida, H; Shimokawa, T; Takiuchi, H; Tominaga, K; Tsujinaka, T; Yamamoto, M; Yano, H | 1 |
| Bougnoux, P; Carrasco, AT; Fumoleau, P; Joly, F; Kerbrat, P; Lhommé, C; Pautier, P; Petit, T; Ringeisen, F; Rixe, O | 1 |
| Adachi, T; Hatoh, T; Matsui, K; Oshita, H; Tanemura, H; Yamada, M | 1 |
| Jensen, S; Krarup-Hansen, A; Pedersen, JV; Riis, L | 1 |
| Chu, P; Ghatage, P; Lucero, CA; Nation, J; Nelson, G | 1 |
| Fracasso, PM; Garcia, AA; Knight, D; Mannel, RS; Muggia, F; Sill, MW; Swensen, R; Tiersten, AD; Warshal, DP | 1 |
| Egawa, C; Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Takatsuka, Y; Takeno, A; Tamura, S; Uji, K; Yoshida, A | 1 |
| Boku, N; Fukutomi, A; Kojima, T; Machida, N; Onozawa, Y; Shukuya, T; Taku, K; Yamazaki, K; Yasui, H | 1 |
| Han, TS; Hur, K; Kim, WH; Kwak, MK; Lee, HJ; Song, SC; Yanagihara, K; Yang, HK; Yu, J | 1 |
| Keating, JP; Kenwright, DN; Saluja, M | 1 |
| Blank, SV; Chen, HX; Christos, P; Curtin, JP; Goldman, N; Liebes, L; Muggia, FM; Runowicz, CD; Sparano, JA | 1 |
| Chua, TC; Deraco, M; Glehen, O; Moran, BJ; Sugarbaker, PH; Yan, TD | 1 |
| Ahn, EH; Eno, ML; Im, DD; Matsuo, K; Rosenshein, NB; Shahzad, MM; Sood, AK | 1 |
| Aoki, D; Aotani, E; Fujiwara, K; Hamano, T; Katsumata, N; Kigawa, J; Nagao, S; Sugiyama, T; Suzuki, M; Takeuchi, M; Yoshikawa, H | 1 |
| Emoto, S; Ishigami, H; Ishihara, K; Kaisaki, S; Kamei, T; Kitayama, J; Konno, T; Nagawa, H; Soma, D; Yamaguchi, H | 1 |
| Imano, M; Kodera, Y; Miyashita, Y; Morita, S; Nakao, A; Sakamoto, J; Sasako, M; Takahashi, N; Tsuburaya, A; Yoshikawa, T | 1 |
| Colson, YL; Grinstaff, MW; Griset, AP; Liu, R; Padera, RF; Schulz, MD; Southard, EB; Wade, JE; Zubris, KA | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Ishikawa, M; Komiyama, M; Komiyama, S; Kurahashi, T; Mikami, M; Tanaka, K; Udagawa, Y | 1 |
| Coleman, RL; Degeest, K; Fujiwara, K; Greer, B; Mannel, RS; Morgan, MA; Rubin, SC; Sill, MW; Waggoner, S; Walker, JL; Yamada, SD | 1 |
| Balthasar, JP; Bernacki, RJ; Shah, DK; Veith, J | 1 |
| Shoji, T | 1 |
| Higashijima, J; Iwata, T; Kurita, N; Miyatani, T; Morimoto, S; Nakao, T; Nishioka, M; Shimada, M; Yoshikawa, K | 1 |
| Emoto, S; Ishigami, H; Kaisaki, S; Kitayama, J; Nagawa, H; Yamaguchi, H; Yamashita, H | 1 |
| Arimoto, T; Kawana, K; Nakagawa, S; Oda, K; Taketani, Y; Yasugi, T | 1 |
| Brantley, E; Fidler, IJ; He, J; Kim, JS; Kim, SJ; Kim, SW; Lehembre, F; Maya, M; Regenass, U; Wu, Q; Yun, SJ; Zhang, F | 1 |
| Azodi, M; Baker, L; Husband, A; Kelly, MG; Mor, G; O'Malley, DM; Rutherford, TJ; Schwartz, PE | 1 |
| Bouquet, W; Ceelen, WP; De Smet, L; De Vos, F; Debergh, I; Deleye, S; Remon, JP; Staelens, S; Van Damme, N; Vervaet, C | 1 |
| Lentz, S; Levine, EA; Parson, EN; Russell, G; Shen, P; Stewart, JH | 1 |
| Arjona-Sánchez, Á; Casado-Adam, Á; Díaz-Nieto, R; Muñoz-Casares, FC; Ortega-Salas, R; Rubio-Pérez, MJ; Rufián-Peña, S | 1 |
| Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Micha, JP; Rettenmaier, MA | 1 |
| Blessing, JA; McMeekin, S; Miller, DS; Muller, CY; Rotmensch, J; Schilder, RJ; Shahin, MS; Tewari, KS; Warshal, DP | 1 |
| Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C | 1 |
| Brady, WE; Coleman, RL; Hoffman, JS; Lentz, SS; McMeekin, DS; Rose, PG; Shahin, MS; Soper, JT | 1 |
| Aranda, E; Arjona-Sánchez, Á; Casado, Á; Díaz, R; Díaz-Iglesias, CJ; Muñoz-Casares, FC; Muñoz-Villanueva, MC; Muntané, J; Naranjo, Á; Ortega, R; Rubio, MJ; Rufián, S | 1 |
| Oehler, MK; Ricciardelli, C; Ween, MP | 1 |
| Berrada, N; Errihani, H; Jalil, A; Kettani, F; Mrabti, H; Zakkouri, FA | 1 |
| Hyde, J; Landrum, LM; Mannel, RS; McMeekin, DS; Moore, KN; Walker, JL | 1 |
| Hayes, JH; Ho, VT; Hornick, JL; Jagannathan, JP; O'Regan, KN; Ramaiya, N; Sneag, DB | 1 |
| An, X; He, Y; Li, Y; Wang, F; Wang, Z; Xu, R; Zhou, N | 1 |
| Debernardo, RL; Dizon, DS; Duska, LR; Eisenhauer, EL; Fracasso, PM; Gould, N; Mannel, RS; Rubin, SC; Sill, MW; Yamada, SD | 1 |
| Fujiwara, K; Kimoto, T; Maeda, T; Makino, T; Nishida, Y; Nomura, Y; Sakata, Y; Tada, H; Takeuchi, N; Ueno, S | 1 |
| Imamoto, H; Imano, M; Itoh, T; Kato, H; Okuno, K; Peng, YF; Satou, T; Shinkai, M; Shiozaki, H; Shiraishi, O; Takeyama, Y; Yasuda, A; Yasuda, T | 1 |
| Chen, RC; Copp, JA; Cummings, ND; Karve, S; Sukumar, R; Wang, AZ; Werner, ME; Zhang, T | 1 |
| Dohi, S; Inoue, M; Kyo, S; Ohno, S; Ohno, Y; Soma, G; Sugiyama, H; Takakura, M | 1 |
| Griffin, CL; Hirte, H; Ledermann, JA; Parmar, MK; Qian, W; Raja, FA; Swart, AM | 1 |
| Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L | 1 |
| Ota, T; Takeshima, N; Takizawa, K | 1 |
| Fujiwara, K; Goto, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T; Ohishi, R | 1 |
| Armstrong, DK; Disilvestro, P; Fracasso, PM; Gould, N; Huang, H; Mannel, RS; Sill, MW; Thaker, PH; Waggoner, S; Walker, JL; Wenzel, L; Yamada, SD | 1 |
| Brown, JV; Buck, M; Chambers, SK; Covens, A; Davy, M; Ghatage, P; Hansen, VL; Karlan, BY; Leath, CA; Nagarkar, RV; Nguyen, H; Oza, AM; Pippitt, CH; Provencher, DM; Richardson, GE; Stepan, DE; Sun, YN; Tassoudji, M; Vergote, IB; Weinreich, DM | 1 |
| Ishikawa, H; Iwazaki, S; Izumi, M; Kakinuma, S; Kamoshita, N; Kawate, S; Kobayashi, I; Kobayashi, J; Makita, F; Nakagami, K; Ohya, T; Okabe, T; Sakamoto, I; Sato, Y; Sunose, Y; Takeyoshi, I; Tanahashi, Y; Tomizawa, N; Yamada, T; Yoshinari, D | 1 |
| Brenton, JD; Crawford, RA; Earl, HM; Gill, AB; Graves, MJ; Griffiths, JR; Hodgkin, C; Jimenez-Linan, M; Joubert, I; Kataoka, MY; Lomas, DJ; McLean, MA; Priest, AN; Sala, E | 1 |
| Itamochi, H; Kigawa, J; Kitada, F; Minagawa, Y; Okada, M; Sato, S; Shimada, M | 1 |
| Aiba, T; Furukawa, K; Hayashi, M; Igarashi, K; Sato, M; Shibuya, H; Sugimura, K; Waguri, N; Yoneyama, O | 1 |
| Abu Shahin, N; Alberts, DS; Chambers, SK; Chow, HH; Clouser, MC; Cohen, JL; Cragun, JM; Cui, H; Hatch, KD; Janicek, MF; Laughren, C; Wright, HM | 1 |
| Gallagher, CJ; Jeyarajah, A; Ledermann, JA; McCormack, M; McDonald, N; McNeish, I; Mould, T; Olaitan, A; Oram, D; Orphanos, G; Reynolds, K; Saha, A; Shepherd, J; Varughese, M; Wilson, P | 1 |
| Li, H; Tong, X; Wang, J; Yang, F | 1 |
| Aghajanian, C; Barlin, JN; Bell-McGuinn, KM; Bou Zgheib, N; Chi, DS; Dao, F; Ferguson, SE; Hensley, ML; Konner, J; Sabbatini, PJ; Tew, WP | 1 |
| Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tan, T; Tani, S | 1 |
| Agaimy, A; Besendörfer, M; Brecht, IB; Carbon, R; Holter, W; Langer, T; Metzler, M; Osinski, D; Rompel, O; Thiel, FC | 1 |
| Gong, C; Luo, F; Qian, Z; Wang, C; Wang, Y; Wu, Q; Zhang, D | 1 |
| Bracke, M; Ceelen, W; Colin, P; De Smet, L; Remon, JP; Van Bocxlaer, J; Vervaet, C | 1 |
| Agnoletti, V; Amadori, A; Ansaloni, L; Catena, F; Cavaliere, D; Coccolini, F; De Iaco, P; Di Battista, M; Framarini, M; Gazzotti, F; Ghermandi, C; Kopf, B; Pinna, AD; Saponara, M; Tauceri, F; Vallicelli, C; Verdecchia, GM | 1 |
| Fortier, AH; Fu, S; Hong, DS; Kurzrock, R; Lim, J; Naing, A; Subbiah, IM; Tsimberidou, AM; Wen, S | 1 |
| Bristow, RE; Chang, SJ; Ryu, HS | 1 |
| Campos, S; Esselen, KM; Growdon, W; Horowitz, NS; Krasner, C; Rodriguez, N | 1 |
| Fuse, N; Goto, M; Hironaka, S; Iwasa, S; Kusaba, H; Nakajima, TE; Nakayama, N; Nishina, T; Shimada, Y; Taira, K; Takahari, D; Yasui, H | 1 |
| Goto, M; Hirata, Y; Kawahara, Y; Kitamura, M; Nakayama, M; Ohta, R; Oneyama, M; Sekikawa, K; Shimoda, Y; Takahashi, Y | 1 |
| Fujiwara, Y; Furukawa, K; Haruki, K; Iwase, R; Misawa, T; Ohashi, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Emoto, S; Hirano, K; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Yamaguchi, H; Yamamoto, N | 1 |
| Aichler, M; Baumgart, A; Blechert, B; Bruchertseifer, F; Essler, M; Feuchtinger, A; Gaertner, FC; Gilbertz, KP; Li, Z; Morgenstern, A; Seidl, C; Senekowitsch-Schmidtke, R; Vallon, M; Walch, AK | 1 |
| Emoto, S; Hidemura, A; Ishigami, H; Kitayama, J; Watanabe, T; Yamaguchi, H; Yamashita, H | 1 |
| Armstrong, DK; DiSilvestro, PA; Fracasso, PM; Gould, N; Mannel, RS; Sill, MW; Thaker, PH; Waggoner, SE; Walker, JL; Yamada, SD | 1 |
| Boaz, M; Golan, A; Levy, T; Menczer, J; Shem, EB; Weiser, R | 1 |
| Lowe, MP; Schwartzberg, LS; Stepanski, EJ; Tillmanns, TD; Walker, MS | 1 |
| Furukawa, H; Imamoto, H; Imano, M; Inoue, K; Itoh, T; Kato, H; Nishida, S; Nishikawa, M; Okuno, K; Peng, YF; Satou, T; Shinkai, M; Shiozaki, H; Takeyama, Y; Tsubaki, M; Yasuda, A; Yasuda, T | 1 |
| Chiba, Y; Furukawa, H; Imamoto, H; Imano, M; Itoh, T; Kato, H; Nishida, S; Okuno, K; Peng, YF; Satou, T; Shinkai, M; Shiozaki, H; Takeyama, Y; Tsubaki, M; Yasuda, A; Yasuda, T | 1 |
| Butler-Manuel, S; Essapen, S; Larbi, E; Madhuri, K; Michael, A; Tailor, A | 1 |
| Alexander, HR; Alimchandani, M; Avital, I; Bartlett, DL; Beresnev, T; Eberhardt, JS; Hassan, R; Hughes, MS; Kalina, P; Kammula, US; Libutti, SK; Pandalai, P; Phan, GQ; Pingpank, JF; Quezado, M; Royal, RE; Rudloff, U; Schaub, NP; Stojadinovic, A | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Nagahara, H; Noda, E; Ohira, M; Sakurai, K; Sawada, T; Tanaka, H | 1 |
| Kondo, J; Nagashima, Y; Nakamura, M; Nishimura, T; Okada, T; Sakata, K | 1 |
| Fujiwara, T; Kagawa, S; Kishimoto, H; Kono, A; Nishizaki, M; Oiwa, M; Uno, F | 1 |
| Antsaklis, A; Bamia, C; Bamias, A; Dimopoulos, MA; Haidopoulos, D; Kakoyianni, K; Kostouros, E; Rodolakis, A; Thomakos, N; Vlahos, G; Zagouri, F | 1 |
| Chu, P; Ghatage, P; Glaze, S; Nation, J; Nelson, G; Teitelbaum, L | 1 |
| Lu, XY; Wang, ML; Wang, X; Yang, JF; Yu, HG; Zhou, LY | 1 |
| Alessandroni, P; Catalano, G; Catalano, V; Fedeli, A; Giordani, P; Graziano, F; Luzi Fedeli, S; Rossi, D; Testa, E | 1 |
| Ficorella, C; Marchetti, P; Narducci, F; Paris, I; Porzio, G; Ricevuto, E | 1 |
| Fujimura, T; Fushida, S; Kinami, S; Miwa, K; Miyamoto, K; Nao, F; Ninomiya, I; Nishimura, G; Ohta, T; Yokogawa, K | 1 |
| Fujimura, T; Furui, N; Fushida, S; Kinami, S; Miwa, K; Miyamoto, K; Ninomiya, I; Nishimura, G; Ohta, T; Yokogawa, K | 1 |
| Moritake, T; Ogura, H; Terauchi, F; Yamamoto, Y | 1 |
| Alvarez, AA; Berchuck, A; Carney, ME; Clarke-Pearson, DL; Havrilesky, LJ; Lancaster, JM; Rodriguez, GC; Sayer, RA; Soper, JT | 1 |
| Cho, H; Imada, T; Kanari, M; Kobayashi, O; Motohashi, H; Sairenji, M; Sano, H; Tsuburaya, A | 1 |
| Beijnen, JH; de Bree, E; Georgoulias, V; Michalakis, J; Romanos, J; Rosing, H; Tsiftsis, DD | 1 |
| Ball, HG; Blessing, JA; DeGeest, K; Hoffman, J; Moore, DH; Rose, PG; Warshal, D | 1 |
| Calderisi, MD; Corona, F; De Petris, L; Di Placido, M; Longo, F; Malizia, A; Marenga, G; Mongardini, M; Patrizi, V; Priore, FM; Schillaci, F; Scirocchi, R; Stagnitti, F; Tiberi, R | 1 |
| Alberts, DS; Glass, T; Goodwin, JW; Hatch, KD; Markman, M; Smith, HO; Taylor, SA; Weiss, GR | 1 |
| Marchettini, P; Mohamed, F; Stuart, OA; Sugarbaker, PH; Yoo, D | 1 |
| Ishiguro, M; Kudoh, H; Murakami, S; Naka, T; Nishidoi, H; Shibata, S; Taniguchi, K; Yamaguchi, Y; Yurugi, E | 1 |
| Alberts, D; Alvarez, RD; Copeland, LJ; Jiang, C; Liu, PY; Markman, M; Monk, B; Wilczynski, S | 1 |
| Kinoshita, H; Kitaura, T; Nakae, S; Onoyama, H; Sainoh, K; Saitoh, Y; Shiroiwa, H; Sugihara, S; Takahashi, T; Takao, S; Toyota, J; Urakawa, T; Yamamoto, M | 1 |
| Aikou, T; Arima, H; Hamada, N; Hokita, S; Ishigami, S; Maeda, S; Miyazono, F; Natsugoe, S; Takao, S; Takatori, H | 1 |
| Gruenigen, VE; McElroy, TM; Waggoner, SE | 1 |
| Aihara, T; Fukunaga, M; Kim, T; Kittaka, N; Kozuma, Y; Miki, H; Ozato, H; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N; Wada, H | 1 |
| Boggess, JF; Boruta, DM; Fowler, WC; Gehrig, PA; Van Le, L; Walton, LA | 1 |
| Alexander, HR; Bartlett, DL; Beresnev, TH; Feldman, AL; Kleiner, DE; Libutti, SK; Liewehr, DJ; Mavroukakis, SM; Pingpank, JF; Steinberg, SM | 1 |
| Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K | 1 |
| Chiba, F; Esato, K; Ikeda, Y; Jinbo, M; Kamei, T; Kurata, S; Mochizuki, K; Moriuchi, H; Nakafuji, Y; Nakayasu, K; Nawata, S; Oka, K; Suto, R; Zempo, N | 1 |
| Imazu, H; Matsubara, T; Nakamura, Y; Ochiai, M; Sakai, W; Sakurai, Y; Tonomura, S; Yoshida, I | 1 |
| Endo, Y; Hamada, A; Hikita, H; Kanai, M; Matsubayashi, Y; Miura, K; Nishikawa, H; Ochi, J; Oe, K; Ogasawara, M; Tada, E; Takeda, Y; Torii, A; Yamakawa, M | 1 |
| Bookman, MA; Herzog, TJ; Look, KY; Rocereto, T; Schol, J; Vinters, J | 1 |
| Belinson, J; Escobar, PF; Markman, M; Rose, P; Webster, K; Zanotti, K | 1 |
| Abraham, R; Cronk, M; Perrin, L | 1 |
| Balat, O | 1 |
| A'Hern, R; Cole, C; Everard, M; Gibbens, I; Gore, M; Hall, G; Harries, M; Jenkins, A; Kaye, S; Moss, C; Perren, T; Pizzada, O; Shah, R | 1 |
| Ho, ES; Hung, MJ; Hwang, SF; Ke, YM; Liu, FS; Lu, CH | 1 |
| Asmar, L; Bailey, CL; Gordon, AN; Messing, MJ; Pippitt, CH; Savage, J; Street, DG; Young, JA | 1 |
| Birk, CL; Brown, JV; Goldstein, BH; Graham, C; Mattison, J; Micha, JP; Rettenmaier, MA | 1 |
| Belinson, J; Markman, M | 1 |
| Beatty, B; Cooper, K; Eltabbakh, GH; Morgan, A; Mount, SL; Simmons-Arnold, L | 1 |
| Camatte, S; Castaigne, D; Dubernard, G; Duvillard, P; Fourchotte, V; Lhommé, C; Morice, P; Pautier, P; Pomel, C; Rey, A; Thoury, A | 1 |
| Aghajanian, C; Anderson, S; Brown, JV; Dizon, D; Dupont, J; Eisenfeld, AJ; Jacobs, A; Mehdi, A; Peters, WA; Rivkin, S; Sabbatini, P; Spriggs, D | 1 |
| Atkinson, R; Coleman, R; Gabra, H; Gordon, A; Hay, A; Jayson, GC; Kaye, SB; Parkin, D; Paul, J; Vasey, PA | 1 |
| Ebuchi, M; Hasegawa, K; Kato, K; Koide, A; Maruyama, M; Maruyama, S; Nagahama, T; Oobu, M; Takashima, I | 1 |
| Fujitani, K; Hirao, M; Tsujinaka, T | 1 |
| Ebisui, C; Fujimoto, T; Fukuchi, N; Hasuike, Y; Hayashi, N; Izawa, H; Sakita, I; Souma, I; Yoshida, T | 1 |
| Hayashidani, Y; Morifuji, M; Murakami, Y; Sasaki, M; Sueda, T; Toge, K; Yokoyama, Y | 1 |
| Fusco, N; Rose, PG; Smrekar, M | 1 |
| Miyade, Y; Ninomiya, M; Ohtani, S; Shimizu, Y; Sugiyama, S | 2 |
| Cathomas, R; Gregory, K; Lowndes, S; Rogerson, M | 1 |
| Camatte, S; Castaigne, D; Dubernard, G; Duvillard, P; Lhommé, C; Morice, P; Pautier, P; Rey, A | 1 |
| Deguchi, Y; Kamimura, K; Kaneko, I; Kii, E; Murata, T; Nonogaki, H; Tanaka, T; Tsubono, M; Yasumizu, R | 1 |
| Aoki, Y; Fukada, T; Horiguchi, K; Kobayashi, J; Kobayashi, N; Miyazaki, M; Morishima, Y; Nakano, M; Shiramatsu, K; Suzuki, I; Tazawa, Y; Toyoda, Y; Yamamoto, K; Yokoyama, K | 1 |
| Akanuma, M; Hata, Y; Kuriyama, H; Nonaka, T; Sawatari, T; Tsuboi, H | 1 |
| Iwabuchi, S; Kashiwagi, H; Takahashi, N; Yamazaki, Y; Yanaga, K | 1 |
| Gao, YN; Li, WF; Liu, JX; Tang, WS; Wang, W | 1 |
| Kietpeerakool, C; Srisomboon, J; Suprasert, P | 1 |
| Asai, S; Dokoh, J; Ishikawa, M; Komiyama, S; Mikami, M; Tsuji, H | 1 |
| Fujiwara, M; Hibi, K; Kodera, Y; Koike, M; Nakanishi, H; Nakao, A; Ohashi, N; Tatematsu, M; Yokoyama, H | 1 |
| Bidus, MA; Elkas, JC; Kyser, K; Rodriguez, M; Rose, GS | 1 |
| Aoyagi, K; Imaizumi, T; Koufuji, K; Miyagi, M; Murakami, N; Shirouzu, K; Yano, S | 1 |
| Kobayashi, O; Tsuburaya, A; Yoshikawa, T | 1 |
| Aratake, K; Itabashi, M; Kameoka, S; Mitsuhashi, M; Ogawa, S; Seshimo, A; Shirotani, N | 1 |
| Carneiro, F; Lima, J; Lopes, JM; Magro, F; Pereira, P; Saraiva, A; Sarmento, C; Tavarela-Veloso, F; Teixeira, A | 1 |
| Fujio, N; Fukuda, Y; Ihara, T; Koyama, I; Osugi, H; Takatori, H; Tsukazaki, T; Tsukazaki, Y | 1 |
| Banba, T; Hatakeyama, K; Kanda, T; Kosugi, S; Ohashi, M; Tanabe, T; Yajima, K | 1 |
| Ami, K; Andou, M; Ganno, H; Ichikawa, S; Ito, T; Kimu, K; Kobo, T; Nagahama, T; Nawa, K; Ohbu, M; Takaba, E; Yamauchi, A | 1 |
| Blessing, J; Connor, J; Hanjani, P; Markman, M; Rubin, SC; Waggoner, S | 1 |
| Bang, YJ; Choi, IS; Heo, DS; Im, SA; Kim, DW; Kim, JH; Kim, NK; Kim, TY; Lee, JS; Lee, KW; Na, Ii; Oh, DY; Shin, H; Song, EK; Yun, T | 1 |
| Armstrong, DK; Baergen, R; Bundy, B; Burger, RA; Copeland, LJ; Huang, HQ; Lele, S; Walker, JL; Wenzel, L | 1 |
| Imada, T; Kunisaki, C; Ohshima, T; Ohtsuka, Y; Sato, T; Yamada, R | 1 |
| Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y | 1 |
| Aihara, T; Kim, C; Miki, H; Nakata, K; Ohzato, H; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Onozawa, Y; Yoshino, T; Zenda, S | 1 |
| Chetrit, A; Golan, A; Levy, T; Menczer, J; Sadetzki, S | 1 |
| Fujioka, T; Hirashima, Y; Kagawa, K; Kitajima, K; Kumamoto, T; Murakami, K; Noguchi, T; Sugi, S | 1 |
| Beijnen, JH; de Bree, E; Georgoulias, V; Michalakis, J; Relakis, K; Romanos, J; Rosing, H; Theodoropoulos, PA; Tsiftsis, DD | 1 |
| Stuart, OA; Sugarbaker, PH; Yan, TD; Yoo, D | 1 |
| Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM | 1 |
| Buhl, A; Chalas, E; DiSilvestro, PA; Fisher, M; Pearl, ML; Valea, FA | 1 |
| Kanamaru, T; Tanaka, K; Yamamoto, M | 1 |
| Higashimoto, M; Maeda, S; Maemura, M; Nagata, K; Noguchi, T; Noma, H; Ogura, O; Takebayashi, Y | 1 |
| Asami, A; Baba, H; Hayashi, N; Okamoto, N; Takeshima, K; Yamafuji, K | 1 |
| Hayashi, T; Murayama, Y; Shimizu, H; Watanabe, N; Yoshizawa, M | 1 |
| Fusco, N; Greer, BE; Horowitz, IR; Markman, M; Rose, PG | 1 |
| Honda, I; Kato, T; Kobayashi, D; Mori, M | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Koutsoukou, V; Papadimitriou, CA | 1 |
| Collado, MV; García Villanueva, A; Pérez de Oteyza, J; Rojo, R; Ruiz-Tovar, J | 1 |
| Hirakawa, K; Inoue, T; Kim, T; Kimura, K; Muguruma, K; Ohira, M; Sawada, T; Toyokawa, T; Yamashita, Y; Yashiro, M | 1 |
| Itoi, K; Mizuno, Y; Nishitai, R; Okamoto, S; Shinohara, H; Shirakata, Y; Taki, Y; Yamagami, K; Yamamoto, M | 1 |
| Hara, A; Iwamoto, S; Izumi, N; Tsunemi, S; Yamamoto, M | 1 |
| Imai, S; Ito, T; Kawamoto, K; Morimoto, Y; Niwano, M; Ogasahara, K; Okabe, M; Paku, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y | 1 |
| Alvarez, J; Campaña, O; Lamas, M; Lorenzo, D; Pérez, J; Rodríguez, MJ; Veiras, S | 1 |
| Ichikawa, K; Okuda, N; Takahashi, K; Yagi, Y | 1 |
| Kawaguchi, A; Yamaguchi, S; Yoshida, K | 1 |
| Corrado, G; Samaritani, R; Sbiroli, C; Vizza, E | 1 |
| Black, D; Fransi, S; Jacques, T; Links, M; Morris, DL; Saunders, V; Yan, TD | 1 |
| Horiba, K; Ishikawa, N; Kanazawa, Y; Katsuta, M; Koizumi, M; Kudoh, H; Ohkawa, K; Seya, T; Shinji, S; Shirakawa, T; Tajiri, T; Tanaka, N; Yamada, T; Yamashita, K; Yokoi, K; Yoshioka, M | 1 |
| Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E | 1 |
| Byrd, L; Clamp, A; Hasan, J; Jayson, GC; Thistlethwaite, FC; Ton, C | 1 |
| Goshima, F; Kasuya, H; Kodera, Y; Nakao, A; Nishiyama, Y; Shimoyama, S; Teshigahara, O | 1 |
| Arakawa, T; Fujii, K; Kaneda, K; Kawamura, C; Kayo, S; Mizuyama, Y; Nakagawa, H; Ueda, Y; Uno, H | 1 |
| Fujimoto, M; Takeda, Y; Takeuchi, K; Tsujino, T; Yoshida, S | 1 |
| Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamaguchi, K; Yamamitsu, S | 1 |
| Boggess, JF; Brady, MF; Burger, RA; Clarke-Pearson, DL; Hanly, M; Lee, RB; Mannel, R; Spriggs, DR; Vaccarello, L | 1 |
| Aydin, Y; Cicin, I; Eralp, Y; Ozluk, Y; Saip, P; Selam, M; Topuz, E; Topuz, S | 1 |
| Hribaschek, A; Lippert, H; Meyer, F; Pross, M; Ridwelski, K; Schneider-Stock, R | 1 |
| du Bois, A; Harter, P; Hilpert, F; Pfisterer, J | 1 |
| Akiyama, J; Hayashi, Y; Iwashita, R; Kobayakawa, M; Masaki, N; Nagaoki, Y; Nagata, N; Nozaki, Y; Oshima, T; Sako, A; Sakurai, T; Tamegai, Y; Uemura, N; Umeda, N; Watanabe, M; Yago, Y | 1 |
| Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Takatsuka, Y; Takiuchi, D; Tamura, S; Tomita, N | 1 |
| Furukawa, N; Haruta, S; Kanayama, S; Kawaguchi, R; Kitanaka, T; Kobayashi, H; Naruse, K; Oi, H; Sado, T; Sakata, M; Yamada, Y; Yoshida, S | 1 |
| Tohya, T; Ujioka, T; Yamaguchi, M | 1 |
| Beijnen, JH; Daskalakis, M; de Bree, E; Filis, D; Kalbakis, K; Melisssourgaki, M; Pilatou, M; Romanos, J; Rosing, H; Sanidas, E; Taflampas, P; Tsiftsis, DD | 1 |
| Fukuda, H; Kamura, T; Konishi, I; Matsumoto, K; Onda, T; Sato, A; Shibata, T; Yoshikawa, H | 1 |
| Abushahin, F; Belinson, J; Fader, AN; Gibbons, H; Markman, M; Rose, P; Starks, D; von Gruenigen, V | 1 |
| Barbachano, Y; Gore, M; Hook, J; Kaye, SB; Linch, M; Stavridi, F | 1 |
| Fujitani, K; Furukawa, H; Goto, M; Imamoto, H; Imamura, H; Imano, M; Ishida, H; Kimura, Y; Narahara, H; Shimokawa, T; Takiuchi, H | 1 |
| Alberts, DS; Alvarez, RD; Bidzinski, M; Bradford, WZ; Clouser, MC; Johnson, G; Kardatzke, DR; Kirn, DH; Loutit, J; Markman, M; Marth, C | 1 |
| Iwata, S; Katoh, H; Kitaoka, A; Masumoto, H; Ohtsuka, K; Yamaki, S | 1 |
| Hayashi, S; Karaki, H; Sugano, I; Sugimoto, K; Suzuki, H; Takayanagi, H; Yamamori, H; Yamamoto, K | 1 |
| Ishida, T; Kameyama, T; Matsuyama, A; Okamoto, M; Okazaki, J; Tsutsui, S; Utsunomiya, T; Yamamoto, M | 1 |
| Akrivos, T; Dertimas, V; Iavazzo, C; Kalinoglou, N; Katsoulis, M; Vorgias, G | 1 |
| Bajorin, DF; Bosl, GJ; Fischer, P; Hutter, HS; Lyn, P; Motzer, RJ; Scher, HI; Schwartz, LH | 1 |
| Donner, LR; Kavanagh, JJ; Kudelka, AP; Mante, R; Silva, E; Wilailak, S | 1 |
| Jenkins, JJ; Mandrell, BN; Pratt, CB; Smiley, LM; Wall, JE | 1 |
| D'Incalci, M; Giavazzi, R; Lucchini, V; Nicoletti, MI | 1 |
| Abbott, BJ; D'Incalci, M; Giavazzi, R; Lucchini, V; Massazza, G; Nicoletti, MI | 1 |
| Francis, P; Hakes, T; Hoskins, W; Markman, M; Rowinsky, E; Schneider, J | 1 |
| Almadrones, L; Barakat, R; Curtin, J; Hakes, T; Hoskins, W; Markman, M | 1 |
| Aikins, JK; Menzin, AW; Rubin, SC; Wheeler, JE | 1 |
| Sharma, A; Sharma, US; Straubinger, RM | 1 |
| Schrijvers, D; van Dam, P; van Oosterom, A | 1 |
| Edwards, CL; Herrada, J; Kavanagh, JJ; Kudelka, AP; Shin, DM; Tornos, C; Verschraegen, CF | 1 |
| Burt, HM; Davis, NL; Demetrick, JS; Hunter, WL; Liggins, RT; Machan, L | 1 |
| Belinson, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Webster, K | 5 |
| Blumenson, LE; Eltabbakh, GH; Hempling, RE; Piver, MS; Recio, FO | 1 |
| Fluellen, L; Fusco, N; Rodriguez, M; Rose, PG | 1 |
| Belinson, J; Fluellen, L; Fusco, N; Horowitz, IR; Jones, E; Kennedy, A; Kulp, B; Markman, M; McGuire, WP; Peterson, G; Rose, PG; Webster, K | 1 |
| Brady, MF; Hanjani, P; Markman, M; Rubin, SC; Spirtos, NM | 1 |
| Belinson, J; Hurteau, J; Kennedy, A; Kulp, B; Markman, M; Peterson, G; Sutton, G; Webster, K | 1 |
| Belinson, JL; Kennedy, AW; Kulp, B; Markman, M; Peterson, G; Rybicki, LA; Webster, KD | 1 |
| Eltabbakh, GH; Hempling, RE; Intengen, ME; Piver, MS; Recio, FO | 1 |
| Cohen, Y; Horowitz, J; Meirovitz, M; Piura, B | 1 |
| Ghamande, SA; Piver, MS | 1 |
| Atkinson, EN; Burke, TW; Gershenson, DM; Lee, JJ; Levenback, C; Morris, M; Silva, EG; Thall, PF; Wharton, JT; Wolf, J | 1 |
| Atkinson, EN; Guedes, Ed; Kavanagh, JJ; Kudelka, AP; Nelson-Taylor, T; Rogers, R; Sittisomwong, T; Steger, M; Verschraegen, CF; Vincent, M | 1 |
| Fowler, JM; Greer, BE; Horowitz, IR; McGuire, WP; Rodriguez, M; Rose, PG; Waggoner, S | 1 |
| Baronius, W; Bokemeyer, C; Clemens, M; Haag, C; Hartmann, JT; Hempel, V; Kanz, L; Kollmannsberger, C; Lingenfelser, T; Quietzsch, D; Schroeder, M | 1 |
| Belinson, JL; Kennedy, AW; Markman, M; Webster, KD; Zanotti, KM | 1 |
| Allen, D; Davison, J; Gates, P; Neesham, D; Planner, R; Prince, HM; Quinn, M; Rischin, D | 1 |
| Markman, M | 1 |
| Piura, B; Rabinovich, A; Yanai-Inbar, I | 1 |
| Berkowitz, RS; Campos, SM; Cook, S; Fuller, AF; Goodman, A; MacNeill, KM; Matulonis, UA; Penson, RT; Seiden, MV; Supko, JG | 1 |
| Kairi-Vasilatou, E; Koutselini, HA; Lazaris, AC; Papayannopoulou, A; Thomopoulou, G | 1 |
| Elit, L; Finn, M; Hirte, H; Kwon, JS; Mazurka, J; Moens, F; Trim, K | 1 |
| Fujiyoshi, K; Harada, C; Ishimatsu, J; Kamura, T; Kawagoe, H; Kawata, T; Nishio, S; Sugiyama, T; Tsunawaki, A | 1 |
| Buekers, T; Buller, RE; Horowitz, JA; Karlan, BY; Kreienberg, R; Pegram, M; Petrauskas, S; Runnebaum, IB; Shahin, M; Slamon, D | 1 |
| Barakat, R; Curtin, J; Hakes, T; Jones, W; Lewis, JL; Markman, M; Phillips, M; Reichman, B; Rowinsky, E; Rubin, S | 1 |
14 review(s) available for paclitaxel and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Optimizing regional chemotherapy for epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2022 |
[Malignant epithelial ovarian cancer: Role of intra peritoneal chemotherapy and hyperthermic intra peritoneal chemotherapy (HIPEC): Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian can
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cisplatin; Fallopian Tube Neoplasms; Female; France; Humans; Hyperthermia, Induced; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Societies, Medical | 2019 |
Treatment strategies for gastric cancer patients with peritoneal metastasis.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Clinical Trials, Phase II as Topic; Epithelial Cell Adhesion Molecule; Humans; Infusions, Parenteral; Molecular Targeted Therapy; Paclitaxel; Peritoneal Neoplasms; Prognosis; Receptor, ErbB-2; Silicates; Stomach Neoplasms; Survival Rate; Titanium | 2014 |
Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Evidence-Based Medicine; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2013 |
Dose-dense approaches to ovarian cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2015 |
Versatility of Particulate Carriers: Development of Pharmacodynamically Optimized Drug-Loaded Microparticles for Treatment of Peritoneal Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Carriers; Drug Design; Humans; Injections, Intraperitoneal; Microspheres; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Polymers | 2015 |
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carboplatin; Combined Modality Therapy; Cystadenofibroma; Diagnosis, Differential; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Irinotecan; Leucovorin; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2015 |
[Ramucirumab - a new anticancer agent].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease-Free Survival; Gastrointestinal Neoplasms; Humans; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Stomach Neoplasms | 2016 |
Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Doxorubicin; Hyperthermia, Induced; Infusions, Parenteral; Mesothelioma; Paclitaxel; Pemetrexed; Perioperative Period; Peritoneal Neoplasms; Survival Rate; Time Factors | 2017 |
Pseudomyxoma Peritonei arising from a mucinous borderline ovarian tumour: Case report and literature review.
Topics: Antineoplastic Agents; Appendix; Carboplatin; Chemotherapy, Adjuvant; Cystadenocarcinoma, Mucinous; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pseudomyxoma Peritonei | 2010 |
Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.
Topics: Antineoplastic Agents; Carcinoma; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Versicans | 2011 |
[A case of malignant peritoneal mesothelioma successfully treated with systemic chemothrapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2012 |
Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Taxoids | 2006 |
Comprehensive management of diffuse malignant peritoneal mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Humans; Hyperthermia, Induced; Mesothelioma; Mitomycin; Paclitaxel; Patient Selection; Peritoneal Neoplasms; Survival Analysis | 2006 |
145 trial(s) available for paclitaxel and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Risk Assessment; Risk Factors; Stomach Neoplasms; Survival Analysis | 2021 |
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asian; Bevacizumab; Black or African American; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Ethnicity; Fallopian Tube Neoplasms; Female; Hispanic or Latino; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Survival Rate; White People | 2022 |
Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gastrectomy; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Stomach Neoplasms; Tegafur; Young Adult | 2022 |
A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Stomach Neoplasms | 2022 |
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms | 2022 |
Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO.
Topics: Adult; Humans; Mesothelioma, Malignant; Paclitaxel; Peritoneal Neoplasms; Prospective Studies | 2022 |
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Duration of Therapy; Female; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2023 |
A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies | 2023 |
Phase II clinical trial of sequential treatment with systemic chemotherapy and intraperitoneal paclitaxel for gastric and gastroesophageal junction peritoneal carcinomatosis - STOPGAP trial.
Topics: Adenocarcinoma; Esophagogastric Junction; Humans; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Quality of Life | 2023 |
Intraperitoneal paclitaxel combined with FOLFOX/CAPOX plus bevacizumab for colorectal cancer with peritoneal carcinomatosis (the iPac-02 trial): study protocol of a single arm, multicenter, phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Humans; Multicenter Studies as Topic; Paclitaxel; Peritoneal Neoplasms | 2023 |
INTRAPERITONEAL CHEMOTHERAPY FOR GASTRIC CANCER WITH PERITONEAL CARCINOMATOSIS: STUDY PROTOCOL OF A PHASE II TRIAL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Stomach Neoplasms; Young Adult | 2023 |
Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome | 2020 |
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival | 2020 |
Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Cisplatin; Combined Modality Therapy; Humans; Hyperthermia, Induced; Mitomycin; Paclitaxel; Perfusion; Peritoneal Neoplasms; Stomach Neoplasms | 2020 |
Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate | 2020 |
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Survival Analysis | 2020 |
Reduction of cycles of neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian or primary peritoneal cancer (ROCOCO): study protocol for a phase III randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Case-Control Studies; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2020 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Logistic Models; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Analysis; Treatment Outcome | 2020 |
MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum.
Topics: Adult; Aged; Benzimidazoles; Cystadenocarcinoma, Serous; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Protein Kinase Inhibitors; Topotecan; Young Adult | 2020 |
Phase 1 Study of Combined Chemotherapy of Nab-Paclitaxel, S-1, and Oxaliplatin for Gastric Cancer with Peritoneal Metastasis (NSOX Study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Myocardial Infarction; Oxaliplatin; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2021 |
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Quinolines | 2021 |
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2017 |
Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2019 |
Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nanoparticles; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Proportional Hazards Models; Salvage Therapy; Stomach Neoplasms; Treatment Outcome | 2019 |
Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovary; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2018 |
Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2018 |
A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Fallopian Tube Neoplasms; Female; Humans; Hydrazines; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2018 |
Safety of intraperitoneal paclitaxel combined with conventional chemotherapy for colorectal cancer with peritoneal carcinomatosis: a phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Patient Safety; Peritoneal Neoplasms; Prognosis; Young Adult | 2019 |
A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyridines | 2019 |
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Stomach Neoplasms; Survival Rate | 2019 |
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Double-Blind Method; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Recombinant Fusion Proteins; Salvage Therapy; Survival Rate | 2019 |
Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2013 |
A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Consolidation Chemotherapy; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Induction Chemotherapy; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Severity of Illness Index; Survival Analysis | 2013 |
A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2013 |
Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasms, Glandular and Epithelial; Observer Variation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Radiography; Single-Blind Method | 2013 |
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models | 2013 |
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
Treatment and prognostic factors in primary peritoneal carcinoma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease-Free Survival; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prevalence; Prognosis; Risk Factors; Survival Rate; Treatment Outcome; Turkey | 2014 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bleomycin; Chorionic Gonadotropin; Cisplatin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; International Agencies; Lenograstim; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Precision Medicine; Prognosis; Recombinant Proteins; Survival Rate; Testicular Neoplasms; Young Adult | 2014 |
A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Nanoparticles; Paclitaxel; Peritoneal Neoplasms | 2015 |
Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236).
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Body Mass Index; CA-125 Antigen; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Obesity; Ovarian Neoplasms; Paclitaxel; Patient Readmission; Peritoneal Neoplasms; Risk Factors; Time Factors | 2015 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cytoreduction Surgical Procedures; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Indoles; Intention to Treat Analysis; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Response Evaluation Criteria in Solid Tumors; Thrombocytopenia; Young Adult | 2016 |
Intraperitoneal chemotherapy hyperthermia (HIPEC) for peritoneal carcinomatosis of ovarian cancer origin by fluid and CO2 recirculation using the closed abdomen technique (PRS-1.0 Combat): A clinical pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carbon Dioxide; Chemotherapy, Cancer, Regional Perfusion; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects | 2016 |
Intravenous versus oral dexamethasone for prophylaxis of paclitaxel-associated hypersensitivity reaction in patients with primary ovarian, fallopian tube and peritoneal cancer: A double-blind randomized controlled trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Animals; Antineoplastic Agents, Phytogenic; Dexamethasone; Double-Blind Method; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2016 |
Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Gr
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis | 2016 |
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Young Adult | 2017 |
Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2017 |
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2017 |
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclosporins; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis | 2008 |
A phase II study of cetuximab/paclitaxel/carboplatin for the initial treatment of advanced-stage ovarian, primary peritoneal, or fallopian tube cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cetuximab; Chemotherapy, Adjuvant; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2008 |
Paclitaxel poliglumex and carboplatin as first-line therapy in ovarian, peritoneal or fallopian tube cancer: a phase I and feasibility trial of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Drug Interactions; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid | 2008 |
A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid | 2008 |
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Humans; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Quality of Life | 2009 |
Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2009 |
Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Peritoneal Neoplasms | 2009 |
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Topotecan | 2009 |
Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents, Phytogenic; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life | 2009 |
Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Tissue Distribution; Treatment Outcome | 2009 |
Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2010 |
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in study.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease Progression; Drug Interactions; Female; Humans; Indoles; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2009 |
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2009 |
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gefitinib; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines | 2010 |
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Polyethylene Glycols; Recombinant Proteins | 2010 |
Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ascites; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Quality of Life; Retrospective Studies; Treatment Failure; Treatment Outcome | 2010 |
Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Fallopian Tube Neoplasms; Female; Gene Amplification; Genes, erbB-1; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Young Adult | 2010 |
A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial).
Topics: Antineoplastic Agents, Phytogenic; Feasibility Studies; Humans; Infusions, Intravenous; Infusions, Parenteral; Japan; Paclitaxel; Patient Selection; Peritoneal Neoplasms; Research Design; Stomach Neoplasms | 2011 |
A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Young Adult | 2011 |
Intraperitoneal infusion of paclitaxel with S-1 for peritoneal metastasis of advanced gastric cancer: phase I study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Ascitic Fluid; Drug Combinations; Female; Humans; Infusions, Parenteral; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2011 |
Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Phase II evaluation of phenoxodiol in combination with cisplatin or paclitaxel in women with platinum/taxane-refractory/resistant epithelial ovarian, fallopian tube, or primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Isoflavones; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Treatment Failure; Treatment Outcome | 2011 |
A phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Sesquiterpenes; Survival Rate; Treatment Outcome | 2010 |
A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Nanoparticles; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2011 |
Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2011 |
Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Skin Neoplasms; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2011 |
Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2011 |
Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2012 |
A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncol
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2012 |
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Double-Blind Method; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Fusion Proteins; Survival Analysis | 2012 |
Weekly paclitaxel in combination with doxifluridine for peritoneally disseminated gastric cancer with malignant ascites.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Dose-Response Relationship, Drug; Female; Floxuridine; Humans; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Time Factors; Treatment Outcome | 2011 |
Phase I trial of intraperitoneal pemetrexed, cisplatin, and paclitaxel in optimally debulked ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Injections, Intraperitoneal; Maximum Tolerated Dose; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pemetrexed; Peritoneal Neoplasms; Prognosis; Survival Rate; Tissue Distribution | 2012 |
Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Doxorubicin; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2012 |
Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms | 2012 |
Multicenter feasibility study of combination therapy with fluorouracil, leucovorin and paclitaxel (FLTAX) for peritoneal disseminated gastric cancer with massive ascites or inadequate oral intake.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Disease-Free Survival; Drug Administration Schedule; Eating; Feasibility Studies; Female; Fluorouracil; Humans; Intestinal Perforation; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2012 |
A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2012 |
Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2013 |
A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Young Adult | 2012 |
Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Humans; Instillation, Drug; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Stomach Neoplasms | 2012 |
Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur; Young Adult | 2013 |
Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Gastrointestinal Diseases; Humans; Hydroxamic Acids; Incidence; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Vorinostat | 2013 |
Efficacy of anthracyclines and paclitaxel as first line chemotherapy in patients with visceral metastases of breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 2002 |
Combination chemotherapy with paclitaxel and intraperitoneal cisplatin for ovarian cancer with disseminated lesions in the peritoneum and the diaphragm.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Cisplatin; Diaphragm; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Muscle Neoplasms; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2002 |
Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2003 |
A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2003 |
Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2003 |
A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Dialysis Solutions; Female; Humans; Hydroxyethyl Starch Derivatives; Infusions, Parenteral; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Statistics, Nonparametric | 2003 |
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2003 |
Weekly paclitaxel infusion as salvage therapy in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Treatment Outcome | 2003 |
Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2004 |
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2004 |
Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Salvage Therapy; Treatment Outcome | 2004 |
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lung; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2004 |
Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy | 2004 |
Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2004 |
Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects | 2004 |
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyglutamic Acid; Taxoids | 2004 |
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Confidence Intervals; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Middle Aged; Neutropenia; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Proportional Hazards Models; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2005 |
Phase I study of a weekly schedule of fixed-dose paclitaxel and escalating doses of cisplatin for recurrent or unresectable gastric cancer in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Feasibility Studies; Female; Gastrectomy; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Japan; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Treatment Outcome | 2005 |
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2006 |
Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Vomiting, Anticipatory | 2005 |
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Survival Analysis | 2006 |
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2006 |
Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Polyethylene Glycols; Survival Analysis; Treatment Outcome | 2007 |
Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols | 2007 |
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies | 2007 |
[A phase I study of intraperitoneal plus intravenous paclitaxel against gastric cancer with peritoneal dissemination (HGCG 0301)].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Female; Gastrectomy; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Thrombocytopenia | 2006 |
Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis | 2007 |
Phase III trial of upfront debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0602.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Peritoneal Neoplasms | 2008 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Floxuridine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Tegafur; Thrombocytopenia | 2008 |
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of prog
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Disease-Free Survival; Female; Humans; Interferon-gamma; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Proteins; Treatment Outcome | 2008 |
Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors.
Topics: Adolescent; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germinoma; Granulocyte Colony-Stimulating Factor; Humans; Male; Mediastinal Neoplasms; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Salvage Therapy; Testicular Neoplasms; Vaginal Neoplasms | 1994 |
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects | 1995 |
Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Papillary; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis | 1996 |
Surgically documented responses to paclitaxel and cisplatin in patients with primary peritoneal carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; Humans; Paclitaxel; Peritoneal Neoplasms | 1996 |
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Treatment Failure | 1998 |
Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate | 1998 |
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Carboplatin; Cisplatin; Cystadenocarcinoma, Papillary; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 1998 |
Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Salvage Therapy; Topotecan | 1999 |
A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Melphalan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 1999 |
Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Statistics, Nonparametric; Survival Analysis; Taxoids | 2000 |
Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Thrombocytopenia | 2000 |
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis | 2000 |
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Doxorubicin; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erythema; Fallopian Tube Neoplasms; Female; Foot Dermatoses; Hand Dermatoses; Humans; Liposomes; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Stomatitis; Stroke Volume | 2000 |
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cisplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2000 |
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Docetaxel; Drug Hypersensitivity; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2001 |
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2001 |
A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Statistics, Nonparametric; Survival Rate; Topotecan | 2001 |
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Topics: Adenoviridae; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Carboplatin; Cohort Studies; Combined Modality Therapy; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Fallopian Tube Neoplasms; Female; Genes, p53; Genetic Therapy; Humans; Mutation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tomography, X-Ray Computed; Transgenes | 2002 |
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Drug Evaluation; Female; Humans; Infusions, Parenteral; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Peritoneum | 1992 |
326 other study(ies) available for paclitaxel and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Novel 1H-pyrrolo[2,3-b]pyridine derivative nortopsentin analogues: synthesis and antitumor activity in peritoneal mesothelioma experimental models.
Topics: Antineoplastic Agents; Cell Line; Humans; Magnetic Resonance Spectroscopy; Mesothelioma; Peritoneal Neoplasms; Pyridines; Spectrophotometry, Ultraviolet | 2013 |
Preclinical Activity of New [1,2]Oxazolo[5,4-e]isoindole Derivatives in Diffuse Malignant Peritoneal Mesothelioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Isoindoles; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Peritoneal Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
Efficacy of conversion surgery after a single intraperitoneal administration of paclitaxel and systemic chemotherapy for gastric cancer with peritoneal metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Humans; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms | 2022 |
Complete metabolic response after carboplatin desensitization in Peritoneal Carcinomatosis.
Topics: Antineoplastic Agents; Carboplatin; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography | 2022 |
Management of HER2-Positive Breast Cancer for a Young Patient with Visceral Crisis-The Adjuvant Role of Lifestyle Changes.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Life Style; Liver Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Receptor, ErbB-2; Trastuzumab | 2022 |
Ultra-high drug loading improves nanoparticle efficacy against peritoneal mesothelioma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Humans; Mesothelioma; Mice; Nanoparticles; Paclitaxel; Peritoneal Neoplasms; Pharmaceutical Preparations | 2022 |
Effects of particle size and release property of paclitaxel-loaded nanoparticles on their peritoneal retention and therapeutic efficacy against mouse malignant ascites.
Topics: Animals; Ascites; Carcinoma; Cell Line, Tumor; Emulsions; Liposomes; Mice; Nanoparticles; Paclitaxel; Particle Size; Peritoneal Neoplasms; Quality of Life | 2022 |
Prognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients.
Topics: Female; Humans; Ki-67 Antigen; Mesothelioma, Malignant; Paclitaxel; Pemetrexed; Peritoneal Neoplasms; Platinum; Prognosis; Retrospective Studies | 2022 |
Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Delivery of Health Care; Fallopian Tubes; Female; Humans; Incidence; Japan; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2022 |
[A Case of Sheath-Like Obstruction of the Entire Catheter in a Short Period of Time after Placement of an Intraperitoneal Access Port].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2022 |
Surgical management of peritoneal metastasis: Opportunities for pharmaceutical research.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Colorectal Neoplasms; Combined Modality Therapy; Humans; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms; Pharmaceutical Preparations; Pharmaceutical Research; Proteomics; Tandem Mass Spectrometry | 2023 |
Cytoreduction and Hyperthermic Intraperitoneal Paclitaxel and Cisplatin for Gastric Cancer with Peritoneal Metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2024 |
[A Long-Term Survival Case of Gastric Cancer with Pyloric Stenosis and Peritoneum Dissemination That Received Intravenous and Intraperitoneal Paclitaxel Combined with S-1 Therapy after Bypass Surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Pyloric Stenosis; Stomach Neoplasms | 2023 |
Primary peritoneal serous papillary carcinoma: a case series.
Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma, Papillary; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2019 |
Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis.
Topics: Adipose Tissue; Animals; Antineoplastic Agents; Bioengineering; Carboxylesterase; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Enzyme Therapy; Female; Irinotecan; Mice, Nude; Molecular Targeted Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prodrugs; Stem Cells | 2019 |
Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Peritoneal Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies | 2020 |
Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma.
Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Esophageal Neoplasms; Female; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Paclitaxel; Peritoneal Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-met; Quinolines; Random Allocation; Receptor, ErbB-2; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
A simple method of quantifying chemotherapy-induced peripheral neuropathy using PainVision PS-2100
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Incidence; Japan; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Pilot Projects; Risk Assessment; Risk Factors; Skin; Young Adult | 2020 |
Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study.
Topics: Adult; Aged; Carboplatin; Cohort Studies; Doxorubicin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Progression-Free Survival; Republic of Korea; Retrospective Studies | 2020 |
Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Neutropenia; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2020 |
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Female; Fluorouracil; Gemcitabine; Heterografts; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Treatment Failure; Trifluridine; Xenograft Model Antitumor Assays | 2020 |
Efficacy of intraperitoneally administered paclitaxel for colorectal cancer with peritoneal metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Humans; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms | 2020 |
Unusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series.
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Female; Humans; Hyperthermic Intraperitoneal Chemotherapy; Male; Mesothelioma, Malignant; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2020 |
Safety, pharmacokinetics and tissue penetration of PIPAC paclitaxel in a swine model.
Topics: Animals; Biopsy; Disease Models, Animal; Female; Hyperthermic Intraperitoneal Chemotherapy; Paclitaxel; Peritoneal Neoplasms; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Swine | 2021 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross-Over Studies; Deoxycytidine; Febrile Neutropenia; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Progression-Free Survival; Registries; Republic of Korea; Survival Rate; Treatment Outcome | 2020 |
Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2021 |
Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Colonic Neoplasms; Cytoreduction Surgical Procedures; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Hyperthermic Intraperitoneal Chemotherapy; Laparoscopy; Length of Stay; Male; Mesothelioma; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm, Residual; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Registries; Severity of Illness Index; Survival Rate; Tumor Burden | 2021 |
ASO Author Reflections: Repeated Intraperitoneal Paclitaxel with Systemic Chemotherapy as the First-Line Treatment for Peritoneal Malignancy.
Topics: Cytoreduction Surgical Procedures; Humans; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms | 2021 |
[A Case of Unresectable Pancreatic Cancer with Massive Cancerous Ascites Responsive to KM-CART].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Female; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms | 2021 |
Therapeutic efficacy of a paclitaxel-loaded nanofibrillated bacterial cellulose (PTX/NFBC) formulation in a peritoneally disseminated gastric cancer xenograft model.
Topics: Animals; Bacteria; Carboxymethylcellulose Sodium; Cellulose; Culture Media; Drug Compounding; Humans; Injections, Intraperitoneal; Male; Mice; Mice, Nude; Nanofibers; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2021 |
Intraperitoneal paclitaxel for pancreatic cancer with peritoneal metastasis.
Topics: Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum | 2021 |
Author response to: Comment on: Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis.
Topics: Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum | 2021 |
Author's reply: Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis (Br J Surg 2020; 107: 1811-1817).
Topics: Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum | 2021 |
Comment on: Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis.
Topics: Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum | 2021 |
Improved prognosis of pancreatic cancer patients with peritoneal metastasis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum; Prognosis; Retrospective Studies | 2021 |
[Primary Peritoneal Carcinoma with Long Term Survival-A Case Report].
Topics: Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Omentum; Paclitaxel; Peritoneal Neoplasms; Positron Emission Tomography Computed Tomography | 2021 |
Prognostic Benefit of ≥6 Cycles of Neoadjuvant Chemotherapy for Advanced Ovarian, Tubal, and Peritoneal Cancers.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies | 2021 |
Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2021 |
Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Survival Rate | 2017 |
Successful Long-term Management with a Single Administration of Tri-weekly Nab-paclitaxel in a Patient with Advanced Gastric Cancer with Peritoneal Dissemination.
Topics: Aged; Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Delivery Systems; Fatal Outcome; Humans; Male; Nanoparticles; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2017 |
Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Induction Chemotherapy; Injections, Intraperitoneal; Laparoscopy; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Lavage; Peritoneal Neoplasms; Prognosis; Retrospective Studies; RNA, Messenger; Stomach Neoplasms; Survival Rate; Tegafur | 2017 |
Poor Prognostic Factors in Patients Undergoing Surgery After Neoadjuvant Chemotherapy for Ovarian, Tubal, or Peritoneal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Turkey | 2017 |
Efficacy and safety of dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube or peritoneal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2017 |
The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies | 2017 |
Eruptive cherry angiomas developing in a patient treated with ramucirumab.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Exanthema; Hemangioma; Humans; Liver Neoplasms; Male; Paclitaxel; Peritoneal Neoplasms; Ramucirumab; Stomach Neoplasms; Withholding Treatment | 2018 |
Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey.
Topics: Antineoplastic Agents; Carcinoma; Cardiac Output; Cisplatin; Colorectal Neoplasms; Cytoreduction Surgical Procedures; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Mesothelioma; Mitomycin; Monitoring, Intraoperative; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Practice Patterns, Physicians'; Spain; Stomach Neoplasms; Surveys and Questionnaires | 2018 |
[A Case of Gastric Cancer with Peritoneal Dissemination Effectively Treated with Ramucirumab and Paclitaxel].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Ramucirumab; Stomach Neoplasms | 2017 |
[A Case of Successful Adjuvant Surgery for the Pancreas Head Cancer with Peritoneal Metastasis].
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peritoneal Neoplasms | 2017 |
Programmed 'triple-mode' anti-tumor therapy: Improving peritoneal retention, tumor penetration and activatable drug release properties for effective inhibition of peritoneal carcinomatosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Drug Carriers; Drug Liberation; Female; Humans; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Peritoneal Neoplasms; Peritoneum | 2018 |
Enzyme-Responsive Charge-Reversal Polymer-Mediated Effective Gene Therapy for Intraperitoneal Tumors.
Topics: A549 Cells; Animals; Drug Delivery Systems; Female; Gene Transfer Techniques; Genes, Transgenic, Suicide; Genetic Therapy; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Peritoneal Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2018 |
Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Cell Proliferation; Cisplatin; Cystadenocarcinoma, Serous; Disease Progression; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neurotoxicity Syndromes; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Progression-Free Survival; Republic of Korea; Survival Rate; Treatment Outcome | 2017 |
Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Length of Stay; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Postoperative Complications; Survival Rate; Time Factors | 2018 |
Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2018 |
Reply to Z. Li et al.
Topics: Cisplatin; Humans; Paclitaxel; Peritoneal Neoplasms | 2019 |
PHOENIX-GC Trial: Underpowered for Significant Results?
Topics: Cisplatin; Humans; Paclitaxel; Peritoneal Neoplasms | 2019 |
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world study.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Italy; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Platinum Compounds; Progression-Free Survival; Proportional Hazards Models; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Treatment Failure | 2019 |
[A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Ramucirumab; Stomach Neoplasms; Tegafur | 2018 |
Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Laparoscopic cytoreductive surgery and HIPEC is effective regarding peritoneum tissue paclitaxel distribution.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Hyperthermia, Induced; Laparoscopy; Lymph Node Excision; Paclitaxel; Pelvic Neoplasms; Peritoneal Neoplasms; Swine; Tissue Distribution | 2019 |
[A Case of Robot-Assisted Conversion Surgery for Gastric Cancer with Peritoneal Dissemination That Responded to Intravenous and Intraperitoneal Paclitaxel Combined with S-1 Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Robotic Surgical Procedures; Stomach Neoplasms; Tegafur | 2019 |
The use of cisplatin plus doxorubicin or paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) for stage IIIC or IV epithelial ovarian cancer: a comparative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Doxorubicin; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Retrospective Studies | 2019 |
Primary peritoneal carcinosarcoma: A report of two cases.
Topics: Abdominal Neoplasms; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Fatal Outcome; Female; Humans; Mixed Tumor, Mullerian; Paclitaxel; Peritoneal Neoplasms | 2019 |
Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, e
Topics: Adult; Aged; Aged, 80 and over; Bevacizumab; Carboplatin; Chemotherapy, Adjuvant; Fallopian Tube Neoplasms; Female; Fertility Preservation; France; Humans; Hyperthermia, Induced; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2019 |
Enhanced anti-tumor efficacy and safety with metronomic intraperitoneal chemotherapy for metastatic ovarian cancer using biodegradable nanotextile implants.
Topics: Absorbable Implants; Animals; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Drug Implants; Female; Humans; Mice, Inbred C57BL; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Textiles | 2019 |
The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Patient Safety; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institut
Topics: Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cytoreduction Surgical Procedures; Doxorubicin; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Length of Stay; Middle Aged; Neoadjuvant Therapy; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Postoperative Complications; Progression-Free Survival; Retrospective Studies | 2019 |
Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2020 |
Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Fallopian Tube Neoplasms; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies | 2019 |
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Biomarkers, Tumor; Carboplatin; Drainage; Female; Humans; Ovarian Neoplasms; Paclitaxel; Paracentesis; Peritoneal Neoplasms; Peritoneum; Prognosis; Translational Research, Biomedical | 2013 |
Localized toxic erythema of chemotherapy during treatment with paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Carboplatin; Erythema; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2014 |
Factors associated with improved toxicity and tolerability of intraperitoneal chemotherapy in advanced-stage epithelial ovarian cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Drug Administration Schedule; Drug Tolerance; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA).
Topics: Adenocarcinoma, Scirrhous; Adult; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Dichloroacetic Acid; Docetaxel; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hyperthermia, Induced; Irinotecan; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Photosensitizing Agents; Prognosis; Silicates; Stomach Neoplasms; Taxoids; Tegafur; Titanium | 2013 |
[Approximately four years of survival benefits for a case of gastric cancer postoperative carcinomatous peritonitis by combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Tegafur; Time Factors | 2013 |
Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Salvage Therapy; Stomach Neoplasms; Survival Rate; Tegafur | 2014 |
Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2013 |
Weekly paclitaxel as second-line chemotherapy in Japanese patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Ascites; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2013 |
Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Folic Acid; Folic Acid Transporters; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols | 2014 |
[A case of rectal stenosis due to peritoneal dissemination from gastric cancer that was treated with chemoradiation therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemoradiotherapy; Constriction, Pathologic; Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Rectal Diseases; Stomach Neoplasms; Tegafur | 2013 |
[A case of unresectable gastric cancer in a patient who maintained a good quality of life with multidisciplinary treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Brain Neoplasms; Combined Modality Therapy; Fatal Outcome; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Pyloric Stenosis; Quality of Life; Stomach Neoplasms | 2013 |
[Repeated occlusion of the intraperitoneal access port for intraperitoneal chemotherapy in a patient with gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Cavity; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Vascular Access Devices | 2013 |
In vivo optical pathology of paclitaxel efficacy on the peritoneal metastatic xenograft model of gastric cancer using two-photon laser scanning microscopy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Green Fluorescent Proteins; Humans; Luminescent Proteins; Mice, Nude; Mice, Transgenic; Microscopy, Confocal; Paclitaxel; Peritoneal Neoplasms; Red Fluorescent Protein; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2015 |
[A case of peritoneal carcinomatosis due to recurrence of primary adenocarcinoma of the ureter treated with weekly paclitaxel].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Fatal Outcome; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Recurrence; Urologic Neoplasms | 2014 |
Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Neoplasms, Multiple Primary; Outpatients; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome | 2013 |
Tumor priming enhances siRNA delivery and transfection in intraperitoneal tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Inhibitor of Apoptosis Proteins; Liposomes; Mice; Mice, Nude; Paclitaxel; Peritoneal Neoplasms; RNA, Small Interfering; Survivin; Transfection; Xenograft Model Antitumor Assays | 2014 |
Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels.
Topics: Animals; Cell Line, Tumor; Female; Humans; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2014 |
Experimental development of an intra-abdominal chemohyperthermia model using a closed abdomen technique and a PRS-1.0 Combat CO2 recirculation system.
Topics: Abdomen; Animals; Antineoplastic Agents; Blood Gas Analysis; Body Temperature; Carbon Dioxide; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Disease Models, Animal; Female; Hemodynamics; Hyperthermia, Induced; Infusions, Parenteral; Paclitaxel; Peritoneal Neoplasms; Swine; Treatment Outcome | 2014 |
Chemotherapy-induced neutropenia as a biomarker of survival in advanced ovarian carcinoma: an exploratory study of the gynecologic oncology group.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models; Treatment Outcome | 2014 |
Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Inhibitor of Apoptosis Proteins; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Survivin; Tumor Suppressor Protein p53 | 2014 |
[A case of unresected gastric cancer that maintained long tumor dormancy by use of paclitaxel+S-1 combination therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
A model based analysis of IPEC dosing of paclitaxel in rats.
Topics: Absorption, Physiological; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chemotherapy, Cancer, Regional Perfusion; Computer Simulation; Dose-Response Relationship, Drug; Female; Humans; Hyperthermia, Induced; Models, Biological; Nonlinear Dynamics; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Rats, Nude; Xenograft Model Antitumor Assays | 2014 |
Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2014 |
[A case of gastric adenosquamous carcinoma with peritoneal dissemination in which treatment with S-1 plus paclitaxel therapy resulted in improved long-term survival].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors | 2014 |
The role of hyperthermic intraperitoneal chemotherapy using paclitaxel in platinum-sensitive recurrent epithelial ovarian cancer patients with microscopic residual disease after cytoreduction.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2015 |
Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytodiagnosis; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Lavage; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2015 |
Postoperative time course and utility of inflammatory markers in patients with ovarian peritoneal carcinomatosis treated with neoadjuvant chemotherapy, cytoreductive surgery, and HIPEC.
Topics: Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carboplatin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Inflammation Mediators; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate | 2015 |
Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Colonic Neoplasms; Combined Modality Therapy; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair Enzymes; Drug Evaluation, Preclinical; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Injections, Intraperitoneal; Lead Radioisotopes; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Paclitaxel; Peritoneal Neoplasms; Radioimmunotherapy; Trastuzumab; Xenograft Model Antitumor Assays | 2014 |
ATP-based chemotherapy response assay in primary or recurrent ovarian and peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Ifosfamide; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests; Sensitivity and Specificity; Taxoids | 2014 |
Comment on: "Experimental development of an intra-abdominal chemohyperthermia model using a closed abdomen technique and a PRS-1.0 Combat CO₂".
Topics: Abdomen; Animals; Antineoplastic Agents; Carbon Dioxide; Chemotherapy, Cancer, Regional Perfusion; Female; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms | 2015 |
Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Cisplatin; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Peritoneum | 2015 |
Reply to Comment on: "Experimental development of an intra-abdominal chemohyperthermia model using a closed abdomen technique and a PRS-1.0 Combat CO₂".
Topics: Abdomen; Animals; Antineoplastic Agents; Carbon Dioxide; Chemotherapy, Cancer, Regional Perfusion; Female; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms | 2015 |
Prolonged response to aflibercept in ovarian cancer relapse: a case report.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carboplatin; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Female; Humans; Lymphatic Metastasis; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A | 2015 |
[A case of primary peritoneal carcinoma successfully treated using Paclitaxel and Carboplatin chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-125 Antigen; Carboplatin; Female; Humans; Membrane Proteins; Paclitaxel; Peritoneal Neoplasms | 2014 |
[A recurrent gastric cancer with peritoneal metastasis 15 years after distal gastrectomy successfully treated with S-1 and weekly intravenous and intraperitoneal injections of Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Combinations; Female; Gastrectomy; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms; Tegafur; Time Factors | 2015 |
Primary peritoneal cancer: study of 14 cases and comparison with epithelial ovarian cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate | 2015 |
Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Blood Proteins; Body Temperature; Cell-Free System; Drug Combinations; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Infusions, Parenteral; Kaplan-Meier Estimate; Laparoscopy; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Platelet Count; Retrospective Studies; Second-Look Surgery; Serum Albumin; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Utility of delayed reading of intradermal test in carboplatin-induced drug hypersensitivity.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Drug Hypersensitivity; Female; Humans; Hypersensitivity, Delayed; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Skin Tests | 2015 |
Primary peritoneal serous psammocarcinoma: a case report.
Topics: Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Calcinosis; Carboplatin; Chemotherapy, Adjuvant; Colectomy; Cytoreduction Surgical Procedures; Female; Humans; Hysterectomy; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Peritoneal Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Gene Silencing; Genetic Therapy; Humans; Inhibitor of Apoptosis Proteins; Injections, Intravenous; Lipids; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; RNA, Neoplasm; RNA, Small Interfering; Survivin; Transfection; Xenograft Model Antitumor Assays | 2015 |
Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cohort Studies; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Severity of Illness Index; Survival Rate; Treatment Outcome | 2015 |
Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin.
Topics: Animals; Apoptosis; Ascites; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Drug Therapy, Combination; Erythromycin; Humans; Mice; Orosomucoid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
[Clinical efficacy of paclitaxel combined with S-1 in the prevention and treatment of gastric cancer with peritoneal metastasis].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2015 |
[Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Melphalan; Mitomycin; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Rats; Rats, Wistar; Triazines | 2015 |
Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cytoreduction Surgical Procedures; Female; Hospitals, High-Volume; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2016 |
Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Esophagogastric Junction; Female; Humans; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplastic Cells, Circulating; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2016 |
A patient with gastric cancer with peritoneal carcinomatosis treated with intraperitoneal chemotherapy who survived more than 5 years receiving repeated laparoscopic examinations: a case report.
Topics: Antineoplastic Agents, Phytogenic; Asian People; Carcinoma; Drug Administration Schedule; Female; Gastrectomy; Humans; Injections, Intraperitoneal; Laparoscopy; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Treatment Outcome | 2016 |
[A Case of Long-Term Survival of a Patient with Gastric Cancer with Peritoneal Dissemination].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Time Factors | 2015 |
[A Case of Double Cancers of the Stomach and Endometrium with Peritoneal Metastasis].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Combinations; Endometrial Neoplasms; Female; Gastrectomy; Humans; Hysterectomy; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Tegafur | 2015 |
[Introduction of Chemotherapy for Advanced Gastric Cancer Showing Oncologic Emergency Caused by Peritoneal Dissemination--Report of Tow Cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Ileus; Jaundice, Obstructive; Male; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2015 |
[A Case of Long-Term Survival in a Patient with Small Intestinal Adenocarcinoma with Peritoneal Dissemination].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Floxuridine; Humans; Intestinal Obstruction; Jejunal Neoplasms; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Time Factors | 2016 |
Does early post-operative intraperitoneal chemotherapy (EPIC) for patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) make a difference?
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cytoreduction Surgical Procedures; Disease-Free Survival; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Young Adult | 2016 |
Paclitaxel-Loaded Polymersomes for Enhanced Intraperitoneal Chemotherapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Humans; Injections, Intraperitoneal; Mice; Paclitaxel; Peritoneal Neoplasms; Polymers; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |
Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for the treatment of primary peritoneal serous carcinoma: Results of a Chinese retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; China; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Docetaxel; Female; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Middle Aged; Mitomycin; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids | 2016 |
[A Patient with Gastric Cancer with Peritoneal Dissemination Who Survived for Five Years after Sequential Chemotherapy with S-1 Followed by Paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Fatal Outcome; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2016 |
Augmentation of response to nab-paclitaxel by inhibition of insulin-like growth factor (IGF) signaling in preclinical pancreatic cancer models.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Immunohistochemistry; Inhibitory Concentration 50; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Pyrazoles; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Somatomedins; Triazines; Xenograft Model Antitumor Assays | 2016 |
Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Propensity Score; Prospective Studies; Treatment Outcome | 2016 |
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for gynecological malignancies: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cohort Studies; Cytoreduction Surgical Procedures; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Sarcoma; Survival Rate; Treatment Outcome; Uterine Neoplasms; Young Adult | 2016 |
Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Hydrogels; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Peritoneal Neoplasms; Polymers; Tissue Distribution | 2016 |
Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Docetaxel; Fallopian Tube Neoplasms; Female; Guideline Adherence; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids | 2016 |
Proof-of-Concept of Polymeric Sol-Gels in Multi-Drug Delivery and Intraoperative Image-Guided Surgery for Peritoneal Ovarian Cancer.
Topics: Animals; Drug Carriers; Drug Delivery Systems; Female; Hydrogels; Injections, Intraperitoneal; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyesters; Polyethylene Glycols; Polymers; Sirolimus; Surgery, Computer-Assisted | 2016 |
Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Autophagosomes; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Humans; Mesothelioma; Mice, Nude; Nanoparticles; Paclitaxel; Peritoneal Neoplasms; Peritoneum | 2016 |
Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2016 |
Hyperthermic intraperitoneal chemotherapy with paclitaxel or cisplatin in patients with stage III-C/IV ovarian cancer. Is there any difference?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2016 |
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxycytidine; Female; Fluorouracil; Gastrectomy; Humans; Infusions, Parenteral; Male; Middle Aged; Oxaloacetates; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Stomach Neoplasms; Survival Rate | 2017 |
Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Injections, Intraperitoneal; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Lavage; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2017 |
[A Case of Primary Peritoneal Cancer Successfully Treated with Debulking Surgery and Postoperative Chemotherapy].
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2016 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2017 |
A novel intraperitoneal metastatic xenograft mouse model for survival outcome assessment of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Disease Models, Animal; Esophageal Neoplasms; Heterografts; Mice; Neoplasm Transplantation; Paclitaxel; Peritoneal Neoplasms | 2017 |
High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation.
Topics: Abdominal Wall; Animals; Antineoplastic Agents, Phytogenic; Drug Compounding; Drug Design; Female; Hyperthermia, Induced; Injections, Intraperitoneal; Nanoparticles; Paclitaxel; Particle Size; Peritoneal Absorption; Peritoneal Neoplasms; Permeability; Rabbits; Surface Properties; Tissue Distribution | 2017 |
[A case of gastric cancer with peritoneal dissemination responding to combination chemotherapy with oral fluoropyrimidine and weekly paclitaxel].
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
A three-year survivor case of gastric cancer with peritoneal dissemination--an outpatient with second-line weekly paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Female; Humans; Middle Aged; Outpatients; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed | 2008 |
Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Combined Modality Therapy; Female; Humans; Immunoglobulin G; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Peritoneal Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Trastuzumab; Xenograft Model Antitumor Assays | 2008 |
Intra-thoracic cytoreduction of stage IV peritoneal malignancy: a case series.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Diaphragm; Female; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms | 2008 |
Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle--a new strategy against peritoneal dissemination of gastric cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Female; Humans; Hyaluronic Acid; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Peritoneal Neoplasms; Pharmaceutical Vehicles; Stomach Neoplasms | 2008 |
Intraperitoneal administration of a small interfering RNA targeting nuclear factor-kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer.
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Female; Genetic Therapy; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Paclitaxel; Peritoneal Neoplasms; RNA, Small Interfering; Stomach Neoplasms; Survival Rate; Time Factors; Transcription Factor RelA; Xenograft Model Antitumor Assays | 2008 |
In vitro cytotoxicity of paclitaxel/beta-cyclodextrin complexes for HIPEC.
Topics: Animals; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Caco-2 Cells; Cell Culture Techniques; Cell Survival; Combined Modality Therapy; Drug Carriers; Excipients; Hot Temperature; Humans; Hyperthermia, Induced; Paclitaxel; Peritoneal Neoplasms; Rats | 2009 |
[Combined pegylated liposomal doxorubicin and carboplatin in the treatment of recurrent epithelial ovarian cancer].
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Female; Humans; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Retrospective Studies; Survival Analysis; Treatment Outcome | 2008 |
Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Injections, Intraperitoneal; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2008 |
An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Outpatients; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Retrospective Studies | 2009 |
Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Cystadenocarcinoma, Serous; Feasibility Studies; Female; Humans; Injections, Intraperitoneal; Intraoperative Care; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Treatment Outcome | 2009 |
Primary peritoneal carcinoma in a young woman with suspected endometriosis.
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy; Carboplatin; Diagnosis, Differential; Endometriosis; Female; Fertility; Gonadotropin-Releasing Hormone; Gonadotropins; Humans; Lymph Nodes; Omentum; Oocytes; Ovary; Paclitaxel; Peritoneal Neoplasms; Recombinant Proteins; Young Adult | 2009 |
[Two advanced gastric cancer cases with peritoneal metastases successfully treated by s-1/paclitaxel combination therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Tegafur | 2009 |
Outcomes associated with different intraperitoneal chemotherapy delivery systems in advanced ovarian carcinoma: a single institution's experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Cisplatin; Fallopian Tube Neoplasms; Female; Humans; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2009 |
Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Carriers; Female; Humans; Injections, Intraperitoneal; Methacrylates; Mice; Mice, Nude; Paclitaxel; Peritoneal Neoplasms; Phosphorylcholine; Stomach Neoplasms; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
Surfactants influence the distribution of taxanes in peritoneal dissemination tumor-bearing rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Ascites; Biological Transport; Carcinoma, Hepatocellular; Cell Line, Tumor; Docetaxel; Female; Glycerol; Injections, Intraperitoneal; Liver Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polysorbates; Rats; Surface-Active Agents; Taxoids; Tissue Distribution | 2010 |
[A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur | 2009 |
Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Estrogen Receptor alpha; Female; Gene Expression Profiling; Humans; Middle Aged; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate | 2009 |
The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2009 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Gastroscopy; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Radiography; Stomach Neoplasms; Tegafur; Treatment Outcome | 2009 |
Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Databases, Factual; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epithelial Cells; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2010 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Blotting, Western; Cell Line, Tumor; Coloring Agents; Enzyme-Linked Immunosorbent Assay; Female; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Iodine Radioisotopes; Mice; Mice, Inbred BALB C; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tetrazolium Salts; Thiazoles; Tissue Distribution; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
[Outcome of therapy for type 4 gastric cancer with peritoneal metastasis--diagnosis by laparoscopy and effect of chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Laparoscopy; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Treatment Outcome | 2009 |
[A case of gastric cancer with peritoneal dissemination which has been alive more than three years responding to intraperitoneal chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Humans; Infusions, Parenteral; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2009 |
[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2010 |
Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Drug Combinations; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis; Tegafur; Tomography, X-Ray Computed | 2010 |
[Strategy of treatment for gastric cancer with peritoneal metastasis].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2010 |
Scleroderma induced by paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Female; Genetic Predisposition to Disease; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Scleroderma, Localized; Sex Factors; Time Factors | 2010 |
Intraperitoneal chemotherapy for advanced ovarian and peritoneal cancers in patients following interval debulking surgery or primary cytoreductive surgery: Tom Baker Cancer Centre experience from 2006 to 2009.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Female; Humans; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2010 |
Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Laparoscopy; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Prospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2010 |
The antitumor effect of a thermosensitive polymeric hydrogel containing paclitaxel in a peritoneal carcinomatosis model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Carriers; Female; Humans; Hydrogels; Luciferases, Firefly; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Peritoneal Neoplasms; Polymers; Stomach Neoplasms; Temperature; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2012 |
Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Female; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Length of Stay; Male; Mesothelioma, Cystic; Paclitaxel; Peritoneal Neoplasms | 2011 |
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Brachytherapy; Brain Neoplasms; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Combined Modality Therapy; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2011 |
A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Japan; Ovarian Neoplasms; Paclitaxel; Patient Selection; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Research Design | 2011 |
Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Female; Humans; Injections, Intraperitoneal; Liver; Methacrylates; Mice; Mice, Inbred BALB C; Nanoparticles; Paclitaxel; Peritoneal Neoplasms; Phosphorylcholine; Solubility; Tissue Distribution | 2011 |
The performance of expansile nanoparticles in a murine model of peritoneal carcinomatosis.
Topics: Albumins; Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Survival; Female; Humans; Mesothelioma; Mice; Mice, Nude; Microscopy, Confocal; Microscopy, Electron, Scanning; Paclitaxel; Peritoneal Neoplasms | 2011 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Expression of TGFß1 and its receptors is associated with biological features of ovarian cancer and sensitivity to paclitaxel/carboplatin.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Immunoenzyme Techniques; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Transforming Growth Factor beta1 | 2011 |
Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Availability; Carboplatin; Disease Models, Animal; Female; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Xenograft Model Antitumor Assays | 2011 |
[A case of gastric cancer with peritoneal dissemination successfully treated by S-1/paclitaxel combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastroscopy; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2011 |
Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Endothelin Receptor Antagonists; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pyrimidines; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model.
Topics: Animals; Antineoplastic Agents; beta-Cyclodextrins; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Disease Models, Animal; Hyperthermia, Induced; Injections, Intraperitoneal; Magnetic Resonance Imaging; Paclitaxel; Peritoneal Neoplasms; Positron-Emission Tomography; Rats; Time Factors; Tumor Burden | 2011 |
Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Databases, Factual; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Middle Aged; Mitomycin; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Peritoneum | 2011 |
Pseudomyxoma peritonei treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: results from a single centre.
Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Humans; Hyperthermia, Induced; Mitomycin; Paclitaxel; Peritoneal Neoplasms; Pseudomyxoma Peritonei | 2011 |
A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Survival Rate; Treatment Outcome | 2010 |
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan | 2011 |
Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Prospective Studies; Treatment Outcome | 2011 |
Aggressive ovarian psammocarcinoma: a case report.
Topics: Antineoplastic Agents; Carboplatin; Cystadenocarcinoma, Serous; Female; Humans; Laparotomy; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2011 |
Peritoneal relapse of testicular seminomatous germ cell tumor treated successfully with salvage chemotherapy and autologous stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Ifosfamide; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Seminoma; Stem Cell Transplantation; Testicular Neoplasms; Transplantation, Autologous | 2011 |
[A case of peritoneal serous papillary carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Serous Membrane; Tomography Scanners, X-Ray Computed | 2011 |
Safety of intraperitoneal administration of paclitaxel after gastrectomy with en-bloc D2 lymph node dissection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Female; Follow-Up Studies; Gastrectomy; Humans; Injections, Intraperitoneal; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Postoperative Complications; Prospective Studies; Safety; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2012 |
Folate-targeted nanoparticle delivery of chemo- and radiotherapeutics for the treatment of ovarian cancer peritoneal metastasis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Combined Modality Therapy; Female; Folic Acid; Humans; Mice; Mice, Nude; Microscopy, Fluorescence; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2011 |
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Topics: Adjuvants, Immunologic; Biomarkers, Tumor; CA-125 Antigen; Cancer Vaccines; Carboplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystadenocarcinoma, Serous; Docetaxel; Female; HLA-A Antigens; HLA-A24 Antigen; Humans; Immunotherapy, Active; Membrane Proteins; Middle Aged; Omentum; Ovarian Neoplasms; Paclitaxel; Peptide Fragments; Peritoneal Neoplasms; Taxoids; Tumor Burden; Vaccines, Subunit; WT1 Proteins | 2011 |
Second-line chemotherapy for carboplatin/paclitaxel-refractory ovarian cancer: are multi-agent chemotherapies of little value truly?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Irinotecan; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2011 |
Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Area Under Curve; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Choline; Contrast Media; Diffusion Magnetic Resonance Imaging; Female; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Spectroscopy; Middle Aged; Organometallic Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed | 2012 |
Feasibility study on biweekly paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Endometrioid; Fallopian Tube Neoplasms; Feasibility Studies; Female; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2012 |
Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2012 |
Prognosis of primary peritoneal carcinoma: effect of cytoreductive surgery combined with neoadjuvant chemotherapy after laparoscopic diagnosis and evaluation: a multi-center trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hysterectomy; Kaplan-Meier Estimate; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Ovariectomy; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salpingectomy | 2012 |
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2012 |
[Two cases of advanced gastric cancer with peritonitis carcinomatosa that showed disappearance of ascites and obtained a good quality of life by using DIF and paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Quality of Life; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
Malignant peritoneal mesothelioma in a 16-year-old girl: presentation of a rare disease.
Topics: Abdominal Pain; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Diagnosis, Differential; Female; Humans; Mesothelioma; Paclitaxel; Peritoneal Neoplasms; Rare Diseases | 2012 |
Efficient inhibition of colorectal peritoneal carcinomatosis by drug loaded micelles in thermosensitive hydrogel composites.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Erythrocytes; Fluorouracil; Hydrogel, Polyethylene Glycol Dimethacrylate; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Peritoneal Neoplasms; Polyesters; Polyethylene Glycols; Rabbits; Temperature | 2012 |
Development of a nanocrystalline Paclitaxel formulation for HIPEC treatment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Crystallization; Female; Microscopy, Electron; Nanotechnology; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Rats | 2012 |
Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Pelvis; Peritoneal Neoplasms; Proportional Hazards Models; Retrospective Studies | 2012 |
Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2012 |
[A long-surviving patient with unresectable advanced gastric cancer treated with S-1 and biweekly paclitaxel combination chemotherapy as second-line treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fatal Outcome; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Tegafur | 2012 |
Inhibition of nuclear factor-κB enhances the antitumor effect of paclitaxel against gastric cancer with peritoneal dissemination in mice.
Topics: Animals; Antineoplastic Agents; Benzamidines; Caspase 3; Caspase 8; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation; Guanidines; Humans; I-kappa B Proteins; Male; Mice; Mice, Nude; Neoplasms, Experimental; NF-kappa B; NF-KappaB Inhibitor alpha; Paclitaxel; Peritoneal Neoplasms; Poly(ADP-ribose) Polymerases; Stomach Neoplasms | 2013 |
Role of intervention for biliary and gastric/intestinal obstruction in gastric cancer with peritoneal metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Drainage; Drug Combinations; Endoscopy, Digestive System; Female; Humans; Intestinal Obstruction; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stents; Stomach Neoplasms; Tegafur | 2012 |
Enhanced efficacy of combined 213Bi-DTPA-F3 and paclitaxel therapy of peritoneal carcinomatosis is mediated by enhanced induction of apoptosis and G2/M phase arrest.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Division; Cell Line, Tumor; Chemoradiotherapy; G2 Phase Cell Cycle Checkpoints; HEK293 Cells; HMGN2 Protein; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Organometallic Compounds; Paclitaxel; Peritoneal Neoplasms; Protein Structure, Tertiary; Radiopharmaceuticals; Treatment Outcome | 2012 |
Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheter-Related Infections; Catheters, Indwelling; Cisplatin; Feasibility Studies; Female; Humans; Infusions, Parenteral; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Treatment Outcome; Vascular Access Devices | 2012 |
Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2012 |
The effect of age on first-line chemotherapy for epithelial ovarian cancer and primary peritoneal carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2013 |
A novel nomogram for peritoneal mesothelioma predicts survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; Bayes Theorem; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Nomograms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate; Young Adult | 2013 |
[A case of far-advanced gastric cancer successfully treated with S-1/paclitaxel/krestin immunochemotherapy, followed by curative resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Immunotherapy; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Proteoglycans; Stomach Neoplasms; Tegafur | 2012 |
[A case report of complete response by weekly paclitaxel and 5'-DFUR combination chemotherapy for recurrenced gastric cancer with peritoneal dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Floxuridine; Gastrectomy; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Recurrence; Stomach Neoplasms | 2012 |
[Stent placement using a double-balloon endoscope for malignant duodenal obstruction with Roux-en-Y Anastomosis-a case report].
Topics: Aged; Anastomosis, Roux-en-Y; Combined Modality Therapy; Double-Balloon Enteroscopy; Duodenal Obstruction; Fatal Outcome; Gastrectomy; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Stents; Stomach Neoplasms | 2012 |
Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Humans; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Survival Rate | 2013 |
Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative.
Topics: Alberta; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Recombinant Proteins; Survival Rate | 2013 |
Hypersensitivity reaction to carboplatin: successful resolution by replacement with cisplatin.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cisplatin; Diagnosis, Differential; Drug Hypersensitivity; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Skin Tests | 2002 |
[Pharmacologic study of intraperitoneal docetaxel in gastric cancer patients with peritoneal dissemination].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Mitomycin; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Taxoids; Vindesine | 2002 |
[Pharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with peritoneal dissemination].
Topics: Adult; Aged; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2002 |
[A case of metastatic gastric cancer responding to weekly administration of paclitaxel as a second-line therapy].
Topics: Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Gastrectomy; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2003 |
Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Carcinoma; Combined Modality Therapy; Docetaxel; Female; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Intraoperative Care; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids; Tissue Distribution | 2003 |
[Peritoneal papillary serous carcinoma: clinical report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cystadenocarcinoma, Papillary; Fatal Outcome; Female; Humans; Paclitaxel; Peritoneal Neoplasms | 2002 |
[A case of advanced gastric cancer with peritoneal metastases responding to bi-weekly paclitaxel therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tomography, X-Ray Computed | 2003 |
[A patient with peritoneal metastasis from gastric cancer who responded to weekly chemotherapy with paclitaxel on the third line and could take meal].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Silicates; Stomach Neoplasms; Titanium | 2003 |
[A case of advanced type 4 gastric cancer with peritonitis dissemination, navel metastasis effectively treated with combined chemotherapy of biweekly paclitaxel (TXL) and TS-1].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; Colonic Diseases; Constriction, Pathologic; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Pyridines; Splenectomy; Stomach Neoplasms; Tegafur; Umbilicus | 2003 |
A case of prolonged carboplatin therapy in a patient with carboplatin hypersensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Hypersensitivity; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 2003 |
[A case of gastric cancer with peritoneal dissemination which showed the intraperitoneal CR by administrating TS-1 orally and paclitaxel intraperitoneally].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Humans; Injections, Intraperitoneal; Male; Oxonic Acid; Paclitaxel; Peritoneal Cavity; Peritoneal Neoplasms; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2003 |
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Combined Modality Therapy; Disease Progression; Female; Fluorouracil; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 2003 |
Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carboplatin; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 2003 |
[Two cases of non-curatively resected scirrhous gastric cancer that responded well to weekly paclitaxel therapy].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Postoperative Care; Quality of Life; Retroperitoneal Neoplasms; Stomach Neoplasms | 2003 |
Weekly administration of paclitaxel attenuated rectal stenosis caused by multiple peritoneal recurrence 8 years after the resection of gastric carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Constriction, Pathologic; Drug Administration Schedule; Female; Gastrectomy; Humans; Paclitaxel; Peritoneal Neoplasms; Rectal Diseases; Recurrence; Stomach Neoplasms; Time Factors; Treatment Outcome | 2003 |
[A case of effective weekly paclitaxel administration for primary lesion of schirrous gastric cancer].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Humans; Male; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms | 2004 |
Case report of a generalized seizure related to Paclitaxel infusion.
Topics: Antineoplastic Agents, Phytogenic; Cystadenocarcinoma, Papillary; Female; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Seizures | 2004 |
A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Infusions, Parenteral; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Second-Look Surgery; Treatment Outcome | 2005 |
Factors associated with cytoreducibility among women with ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2004 |
Prognosis of stage III or IV primary peritoneal serous papillary carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Treatment Outcome | 2004 |
[A case of gastric cancer with peritoneal dissemination which shows a remarkable efficacy by a weekly administration of paclitaxel intraperitoneally].
Topics: Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Drug Administration Schedule; Female; Humans; Injections, Intraperitoneal; Neoplasm Seeding; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Treatment Outcome | 2004 |
[Safety of intraperitoneal chemotherapy with paclitaxel in gastric cancer patients with peritoneal dissemination].
Topics: Aged; Antineoplastic Agents, Phytogenic; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasm Seeding; Paclitaxel; Peritoneal Neoplasms; Safety; Stomach Neoplasms | 2004 |
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Hydronephrosis; Lymph Node Excision; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Pyridines; Stents; Stomach Neoplasms; Tegafur | 2004 |
[A case of recurrent gastric cancer with malignant ascites responding dramatically to chemotherapy with paclitaxel infused systemically and intraperitoneally].
Topics: Aged; Antineoplastic Agents, Phytogenic; Ascites; Drug Administration Schedule; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Neoplasm Staging; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2004 |
[A case report of recurrent gastric cancer in which combination chemotherapy with paclitaxel and 5-fluorouracil made for successful biliary stenting and improvement in QOL].
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Biliary Tract; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Humans; Infusions, Intravenous; Infusions, Parenteral; Jaundice, Obstructive; Lymph Node Excision; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stents; Stomach Neoplasms | 2005 |
Primary peritoneal carcinoma with acute renal failure: successful treatment with chemotherapy.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Female; Humans; Paclitaxel; Paraneoplastic Syndromes; Peritoneal Neoplasms; Renal Dialysis; Treatment Outcome | 2005 |
Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carcinoma, Papillary; Combined Modality Therapy; Cystadenocarcinoma, Serous; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2005 |
[Weekly paclitaxel administration and intraabdominal CBDCA injection possibly beneficial treatment for recurrent breast cancer associated with metastatic ovarian cancer and peritoneal dissemination after operation--a case report].
Topics: Adenocarcinoma, Scirrhous; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Administration Schedule; Female; Floxuridine; Humans; Hysterotomy; Infusions, Intravenous; Injections, Intraperitoneal; Middle Aged; Nitriles; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Triazoles | 2005 |
[A case of non-curatively resected scirrhous gastric cancer successfully treated over 2 years with weekly administration of paclitaxel].
Topics: Adenocarcinoma, Scirrhous; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Female; Gastrectomy; Humans; Lymph Nodes; Lymphatic Metastasis; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Splenectomy; Stomach Neoplasms; Survivors | 2005 |
[A case of advanced gastric cancer with peritoneal dissemination effectively treated by combined chemotherapy of paclitaxel (TXL) and TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2005 |
[Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III-IV ovarian papillary serous carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Papillary; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Taxoids | 2005 |
Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Sectional Studies; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2005 |
A pilot study of weekly docetaxel therapy for recurrent ovarian cancer, tubal cancer, and primary peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Docetaxel; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Platinum Compounds; Taxoids; Treatment Outcome | 2005 |
Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Green Fluorescent Proteins; Humans; Immunohistochemistry; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Peritoneal Neoplasms; Plasmids; Platelet Endothelial Cell Adhesion Molecule-1; Stomach Neoplasms; Survival Analysis; Survival Rate; Transfection; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Spontaneous pregnancy following cytoreduction with peritonectomy and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fertility; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Parenteral; Mesothelioma; Paclitaxel; Peritoneal Neoplasms; Pregnancy | 2006 |
[Peritoneal dissemination of scirrhous type 4 gastric cancers].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Etoposide; Female; Gastrectomy; Humans; Immunotherapy; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2005 |
[Treatment strategy for primary gastric cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Lymph Node Excision; Methotrexate; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2005 |
[Prediction and treatment of peritoneal dissemination in gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Floxuridine; Humans; Ileus; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Cavity; Peritoneal Lavage; Peritoneal Neoplasms; Predictive Value of Tests; Prognosis; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2005 |
Colon stenosis in a patient with ulcerative colitis as a manifestation of mixed müllerian tumor of the peritoneum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colitis, Ulcerative; Colon; Constriction, Pathologic; Endoscopy, Gastrointestinal; Female; Humans; Middle Aged; Mixed Tumor, Mullerian; Paclitaxel; Peritoneal Neoplasms | 2005 |
[A case of advanced gastric cancer with direct invasion of the transverse colon responding to paclitaxel/5'-DFUR combined therapy].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Colon, Transverse; Colonic Neoplasms; Drug Administration Schedule; Floxuridine; Humans; Ileus; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms | 2005 |
[Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[A case of ascities decrease in malignant peritoneal mesothelioma by weekly intra-peritoneal administration of cisplatin and paclitaxel].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Humans; Infusions, Parenteral; Male; Mesothelioma; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 2005 |
[Low-dose weekly paclitaxel therapy proved useful for a case of recurrent gastric cancer with clinically latent hepatic cirrhosis].
Topics: Aged; Anastomosis, Roux-en-Y; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Administration Schedule; Gastrectomy; Humans; Liver Cirrhosis; Male; Neoplasm Invasiveness; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2006 |
[A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Male; Mitomycin; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survivors; Tegafur | 2006 |
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated over 1 year 8 months with combined chemotherapy of paclitaxel and TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2006 |
Weekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2006 |
Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Physical Examination | 2006 |
[Successful bi-weekly paclitaxel treatment of an AFP-producing gastric cancer patient with peritoneal dissemination and multiple liver metastasis].
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2006 |
[A case of long-term survival of gastric cancer with peritoneal metastasis effectively treated by TS-1 and paclitaxel (PTX) combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Constriction, Pathologic; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Sigmoid Diseases; Stomach Neoplasms; Tegafur | 2006 |
[A case of malignant peritoneal mesothelioma successfully treated with carboplatin and paclitaxel].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Mesothelioma; Paclitaxel; Peritoneal Neoplasms; Remission Induction | 2006 |
[A long-term survival case after resection for umbilical metastasis from gastric cancer treated with weekly paclitaxel].
Topics: Abdominal Neoplasms; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Survivors; Umbilicus | 2006 |
[A case of recurrent gastric cancer effectively treated by combined chemotherapy of weekly paclitaxel (PTX) and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Liver Neoplasms; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms | 2006 |
[A case of advanced gastric cancer with peritoneal metastasis that responded to paclitaxel plus 5-FU therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Humans; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms | 2006 |
Papillary serous carcinoma of peritoneum: presentation of 2 cases.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Postoperative Care; Radiography, Abdominal; Time Factors; Tomography, X-Ray Computed; Topotecan; Treatment Outcome | 2006 |
[A case of advanced gastric cancer with malignant ascites responding to weekly paclitaxel therapy].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Agents, Phytogenic; Ascites; Drug Administration Schedule; Female; Humans; Hydronephrosis; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2006 |
[A case of paclitaxel-resistant cancerous ascites secondary to gastric carcinoma responding well to TS-1 therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Ascites; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pylorus; Stomach Neoplasms; Tegafur | 2006 |
[A case report of advanced gastric cancer with carcinomatous ascites successfully treated by outpatient chemotherapy].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
[Weekly paclitaxel therapy effective for gastric cancer with obstructive jaundice due to peritoneal dissemination--a case report].
Topics: Antineoplastic Agents, Phytogenic; Ascites; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Jaundice, Obstructive; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms | 2007 |
[Anesthetic management for scheduled peritonectomy and hyperthermic intraperitoneal chemotherapy in 20 patients].
Topics: Adult; Aged; Analgesia, Epidural; Anesthesia, General; Anesthesia, Inhalation; Anesthesia, Intravenous; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colloids; Combined Modality Therapy; Crystalloid Solutions; Diuretics; Erythrocyte Transfusion; Female; Fever; Fluid Therapy; Fluorouracil; Humans; Hyperthermia, Induced; Hypotension; Intraoperative Complications; Isotonic Solutions; Male; Middle Aged; Mitomycin; Monitoring, Intraoperative; Paclitaxel; Peritoneal Neoplasms; Peritoneum; Plasma; Postoperative Complications; Prospective Studies; Vasoconstrictor Agents | 2006 |
[A case of recurrent gastric cancer with peritoneal dissemination responding to doxifluridine/paclitaxel combination chemotherapy as third-line treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Floxuridine; Gastrectomy; Humans; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Splenectomy; Stomach Neoplasms | 2007 |
[A case of scirrhous gastric cancer with peritoneal metastases successfully treated by combined chemotherapy of biweekly paclitaxel and TS-1 followed by curative resection].
Topics: Adenocarcinoma, Scirrhous; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Routes; Gastrectomy; Humans; Lymph Node Excision; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Silicates; Stomach Neoplasms; Titanium | 2007 |
Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colonic Neoplasms; Colostomy; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Epoetin Alfa; Erythropoietin; Fatal Outcome; Female; Follow-Up Studies; Hemorrhage; Humans; Intestinal Obstruction; Karnofsky Performance Status; Laparotomy; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Palliative Care; Peritoneal Neoplasms; Recombinant Proteins; Salvage Therapy; Topotecan; Urinary Bladder Neoplasms; Vitamins | 2007 |
Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy--a journey to becoming a Nationally Funded Peritonectomy Center.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Australia; Female; Fluorouracil; General Surgery; Humans; Infusions, Parenteral; Intraoperative Care; Learning; Male; Middle Aged; Morbidity; Mortality; Paclitaxel; Peritoneal Lavage; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Time Factors; Treatment Outcome | 2007 |
[Three advanced gastric cancer patients successfully treated by combination therapy of paclitaxel and cisplatin].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Humans; Leukopenia; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms | 2007 |
[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedule; Fluorouracil; Gastroscopy; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Pyloric Stenosis; Quality of Life; Stomach Neoplasms; Survivors | 2007 |
Weekly paclitaxel in the treatment of recurrent ovarian carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome | 2007 |
Enhanced efficacy of herpes simplex virus mutant HF10 combined with paclitaxel in peritoneal cancer dissemination models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Genetic Vectors; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Paclitaxel; Peritoneal Neoplasms; Simplexvirus | 2007 |
[Case of advanced gastric cancer successfully treated with chemotherapy of weekly paclitaxel].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Cisplatin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2007 |
Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel.
Topics: Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Female; Humans; Infusions, Parenteral; Mesothelioma; Paclitaxel; Peritoneal Neoplasms; Radiotherapy, Adjuvant | 2007 |
[The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms | 2007 |
Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2008 |
Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Injections, Intraperitoneal; Injections, Intravenous; Liver Neoplasms, Experimental; Male; Paclitaxel; Peritoneal Neoplasms; Rats; Rats, Inbred ACI; Rats, Inbred Strains | 2007 |
[Peritoneal carcinomatosis in ovarian cancer. Methods and treatment results].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Female; Humans; Infusions, Intravenous; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Reoperation; Survival Rate | 2007 |
[A case of recurrent gastric cancer with peritoneal dissemination--prolonging life and good QOL by chemotherapy with combined use of paclitaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoembryonic Antigen; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Quality of Life; Sensitivity and Specificity; Stomach Neoplasms | 2007 |
Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Hydronephrosis; Infusions, Parenteral; Liver Neoplasms; Male; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2007 |
Peritoneal disseminated recurrence and lung metastasis after surgery for stage IA uterine papillary serous carcinoma of the endometrium: a case report.
Topics: Antineoplastic Agents; Carboplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 2008 |
[Successful treatment of primary peritoneal carcinoma with paclitaxel and carboplatin combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Humans; Paclitaxel; Peritoneal Neoplasms | 2008 |
Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Cancer, Regional Perfusion; Female; Humans; Hyperthermia, Induced; Infusions, Parenteral; Intraoperative Period; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2008 |
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Treatment Outcome | 2008 |
Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2008 |
[A case report of curative resection for gastric cancer with peritoneal dissemination successfully treated by combined chemotherapy of S-1 and paclitaxel].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Gastrectomy; Humans; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2008 |
[A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Methotrexate; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2008 |
[A case of advanced gastric cancer with Schnitzler's metastases effectively treated by the combination of paclitaxel and S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Combinations; Female; Humans; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2008 |
Primary peritoneal serous papillary carcinoma: clinical and laboratory characteristics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite; Ascites; CA-125 Antigen; Carboplatin; Cisplatin; Constipation; Cystadenocarcinoma, Serous; Female; Gynecologic Surgical Procedures; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies; Weight Gain | 2008 |
Peritoneal papillary serous carcinoma: response to Taxol in platinum resistant disease.
Topics: Carboplatin; Cystadenocarcinoma, Papillary; Drug Resistance; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 1995 |
Effectiveness of paclitaxel in treating papillary serous carcinoma of the peritoneum in an adolescent.
Topics: Adolescent; Cystadenocarcinoma, Papillary; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Remission Induction | 1995 |
Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Ascites; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids; Transplantation, Heterologous | 1994 |
Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice.
Topics: Animals; Female; Humans; Injections, Intravenous; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Remission Induction | 1993 |
Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Carriers; Drug Screening Assays, Antitumor; Female; Leukemia P388; Life Expectancy; Liposomes; Mice; Mice, Inbred DBA; Paclitaxel; Peritoneal Neoplasms | 1996 |
CA 125: a misleading tumor marker?
Topics: Antineoplastic Agents, Phytogenic; CA-125 Antigen; Cystadenocarcinoma, Mucinous; Docetaxel; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Taxoids | 1996 |
Remission with carboplatin of paclitaxel resistant primary peritoneal papillary serous carcinoma: case report.
Topics: Aged; Antineoplastic Agents; Carboplatin; Cystadenocarcinoma, Papillary; Drug Resistance; Female; Humans; Paclitaxel; Peritoneal Neoplasms | 1997 |
The development of a novel intraperitoneal tumor-seeding prophylactic.
Topics: Animals; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Glioblastoma; Injections, Intraperitoneal; Microspheres; Neoplasm Seeding; Neoplasm Transplantation; Paclitaxel; Peritoneal Neoplasms; Rats; Rats, Wistar | 1997 |
Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Carcinoma; Cause of Death; Drug Hypersensitivity; Endometrial Neoplasms; Female; Fever; Genital Neoplasms, Female; Humans; Infusions, Intravenous; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Remission Induction; Retrospective Studies; Sepsis; Thrombocytopenia; Treatment Outcome | 1997 |
Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Survival Rate | 1997 |
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Treatment Outcome | 1998 |
Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 1998 |
Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cisplatin; Cystadenocarcinoma, Papillary; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms | 1998 |
Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cisplatin; Combined Modality Therapy; Female; Humans; Mesothelioma; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 1999 |
Dermatomyositis and peritoneal papillary serous carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Ascites; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Dermatomyositis; Female; Humans; Hysterectomy; Laparoscopy; Laparotomy; Mucin-1; Paclitaxel; Peritoneal Neoplasms; Pleural Effusion | 1999 |
Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Disease-Free Survival; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies | 2000 |
Prolonged symptom-free survival in a patient with persistent primary peritoneal carcinoma and a rising CA-125: a note of caution.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cystadenocarcinoma, Papillary; Disease-Free Survival; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Predictive Value of Tests | 2001 |
Psammomacarcinoma of the peritoneum.
Topics: Adnexa Uteri; Aged; Antineoplastic Agents; Ascitic Fluid; Biomarkers, Tumor; CA-125 Antigen; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma; Female; Humans; Hysterectomy; Jejunum; Omentum; Paclitaxel; Peritoneal Neoplasms; Tomography, X-Ray Computed; Ultrasonography | 2001 |
Papillary serous carcinoma of peritoneum: case study and review of the literature on the differential diagnosis of malignant peritoneal tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Nucleus; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Diagnosis, Differential; Female; Humans; Mesothelioma; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2001 |
A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
Topics: Administration, Oral; Cohort Studies; Dexamethasone; Diphenhydramine; Drug Hypersensitivity; Female; Glucocorticoids; Histamine H1 Antagonists; Histamine H2 Antagonists; Humans; Injections, Intravenous; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Ranitidine; Retrospective Studies | 2002 |
[A case of extraovarian primary peritoneal carcinoma successfully treated with weekly paclitaxel].
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents, Phytogenic; Cisplatin; Cystadenocarcinoma, Papillary; Drug Administration Schedule; Female; Humans; Paclitaxel; Peritoneal Neoplasms | 2002 |